

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese- language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS EXPRESS	JUNE 27 08		CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:29:01 ON 17 NOV 2008

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:29:17 ON 17 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10582124.str



chain nodes :

7 8 9 10 11 12 13 20 21

ring nodes :

1 2 3 4 5 6 14 15 16 17 18 19

```

chain bonds :
1-8  5-7  8-9  8-20  9-10  10-11  11-12  12-13  12-21  13-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19
exact/norm bonds :
5-7  8-9  9-10  10-11  12-21  13-15  14-15  14-19  15-16  16-17  17-18  18-19
exact bonds :
1-8  8-20  11-12  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

```

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS


```

L1            STRUCTURE UPLOADED

```

=> d l1
L1 HAS NO ANSWERS
L1            STR

```



Structure attributes must be viewed using STN Express query preparation.

```

=> s l1 fam ful
FULL SEARCH INITIATED 12:29:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -            66 TO ITERATE

```

```

100.0% PROCESSED            66 ITERATIONS            0 ANSWERS
SEARCH TIME: 00.00.01

```

L2            0 SEA FAM FUL L1

```

=> s l1 sss ful
FULL SEARCH INITIATED 12:29:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -            118 TO ITERATE

```

```

100.0% PROCESSED            118 ITERATIONS            0 ANSWERS
SEARCH TIME: 00.00.01

```

L3 0 SEA SSS FUL L1

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

248.01

248.22

STN INTERNATIONAL LOGOFF AT 12:29:50 ON 17 NOV 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications

NEWS 21 OCT 24 CHEMLIST enhanced with intermediate list of  
pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:03:06 ON 17 NOV 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:03:15 ON 17 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2  
DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10582124a.str



```

chain nodes :
7 8 9 10 11 12 19 20
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
1-7 7-8 7-19 8-9 9-10 10-11 11-12 11-20 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
7-8 8-9 9-10 11-20 12-14 13-14 13-18 14-15 15-16 16-17 17-18
exact bonds :
1-7 7-19 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss ful

FULL SEARCH INITIATED 13:03:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 118 TO ITERATE

100.0% PROCESSED 118 ITERATIONS

31 ANSWERS

SEARCH TIME: 00.00.01

L2 31 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 13:03:35 ON 17 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21

FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2

L3 75 L2

=> s l3 and (amyotroph? or als)

7910 AMYOTROPH?

6582 ALS

L4 8 L3 AND (AMYOTROPH? OR ALS)

=> d l4 ibib abs 1-8

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:918262 CAPLUS

DOCUMENT NUMBER: 149:258394

TITLE: Arimoclomol at dosages up to 300 Mg/day is well tolerated and safe in amyotrophic lateral sclerosis

AUTHOR(S): Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson,

Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui;  
 Shui, Amy; Schoenfeld, David; Brown, Robert H.;  
 Wieland, Scott; Barber, Jack R.  
 CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials  
 Unit, Massachussets General Hospital, Charlestown, MA,  
 02129, USA  
 SOURCE: Muscle & Nerve (2008), 38(1), 837-844  
 CODEN: MUNEDE; ISSN: 0148-639X  
 PUBLISHER: John Wiley & Sons, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral  
 sclerosis (ALS) that amplifies heat shock protein gene  
 expression during cell stress. The objectives of the present study were  
 to assess the safety, tolerability, and pharmacokinetics of arimoclomol in  
 ALS. Eighty-four participants with ALS received  
 arimoclomol at one of three oral doses (25, 50, or 100 mg three times  
 daily) or placebo. The primary outcome measure was safety and  
 tolerability. A subset of 44 participants provided serum and  
 cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants  
 who completed 12 wk of treatment could enroll in a 6-mo open-label study.  
 Arimoclomol at doses up to 300 mg/day was well tolerated and safe.  
 Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life  
 did not change with continued treatment. Arimoclomol CSF levels increased  
 with dose. Arimoclomol was shown to be safe, and it crosses the  
 blood-brain barrier. Serum pharmacokinetic profiles support dosing of  
 three times per day. An efficacy study in ALS is planned.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:411857 CAPLUS  
 DOCUMENT NUMBER: 148:410753  
 TITLE: Composition comprising hydroxyamine compound for  
 treating diseases associated with neurodegeneration  
 INVENTOR(S): Barber, Jack R.  
 PATENT ASSIGNEE(S): Cytrx Corporation, USA  
 SOURCE: PCT Int. Appl., 119pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008039514	A1	20080403	WO 2007-US20853	20070926
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080227813	A1	20080918	US 2007-904534	20070926
PRIORITY APPLN. INFO.:			US 2006-847606P	P 20060926
			US 2006-852791P	P 20061018



OTHER SOURCE(S): MARPAT 148:410753

AB The present invention relates to methods for treating diseases, conditions or disorders using hydroxyamine compds., and in particular, N-[2-hydroxy-3- (1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, alone or in combination with one or more other therapeutic agents, for the treatment of conditions, disorders or diseases associated with neurodegeneration in the central nervous system. The present invention also relates to pharmaceutical compns. comprising hydroxyamine compds., an addnl. therapeutic agent and a pharmaceutically acceptable carrier and methods for treating diseases using them. Thus, capsule was prepared containing N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride 25 mg, MC cellulose 252 mg, and talc 3 mg.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.

SOURCE: PCT Int. Appl., 127pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080044390	A1	20080221	US 2007-891552	20070810
----------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.:	US 2006-837448P	P	20060811
	US 2007-898479P	P	20070131
	US 2007-925777P	P	20070423
	US 2007-958832P	P	20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected,

selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mols. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1424894 CAPLUS  
DOCUMENT NUMBER: 148:492092  
TITLE: Heat shock proteins and protection of the nervous system  
AUTHOR(S): Brown, Ian R.  
CORPORATE SOURCE: Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.  
SOURCE: Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158  
CODEN: ANYAA9; ISSN: 0077-8923  
PUBLISHER: Blackwell Publishing, Inc.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it assoc. with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:576156 CAPLUS  
DOCUMENT NUMBER: 146:514797  
TITLE: Use of (2-hydroxy-3-(1-piperidinyl)-propoxy)-pyridine carboximidoyl chloride for treatment of selected neurological diseases  
INVENTOR(S): Karpati, Gyoergy; Molnar, Maria Judit  
PATENT ASSIGNEE(S): Hung.  
SOURCE: Hung. Pat. Appl., 9pp.  
CODEN: HUXXCV  
DOCUMENT TYPE: Patent  
LANGUAGE: Hungarian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----  
HU 9904451                      A2        20021128                      HU 1999-4451                      19991201  
PRIORITY APPLN. INFO.:                      HU 1999-4451                      19991201

AB    The subject of the invention is the new therapeutic application of [2-hydroxy-3-(1-piperidinyl)-propoxy] pyridine-carboxyimido-yl chloride-maleate to treat sporadic amyotrophic lateral sclerosis, Friedreich disease, mitochondrial diseases accompanied by the damage of oxidative phosphorylation (OXPHOS) and in the case of inclusion testes myositis, in the presymptomatic and symptomatic phase, to prevent the harmful effects of primary etiol. factors and to alleviate the progression and clin. symptoms of the disease. According to the invention, the pharmaceutically acceptable derivative of the [2-hydroxy-3-(1-piperidinyl)propoxy]-pyridine carboxy imido-yl-chloride-maleate is used together with a pharmaceutically acceptable adjuvant, diluter or carrier in the neurol. clin. pictures defined above.

L4    ANSWER 6 OF 8    CAPLUS    COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:                      2006:598700    CAPLUS  
DOCUMENT NUMBER:                      145:499471  
TITLE:                                  Neuroprotective agents for clinical trials in ALS  
AUTHOR(S):                              Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.  
CORPORATE SOURCE:                      Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA  
SOURCE:                                  Neurology (2006), 67(1), 20-27  
CODEN: NEURAI; ISSN: 0028-3878  
PUBLISHER:                              Lippincott Williams & Wilkins  
DOCUMENT TYPE:                          Journal; General Review  
LANGUAGE:                                English

AB    A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.

REFERENCE COUNT:                      86        THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4    ANSWER 7 OF 8    CAPLUS    COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:                      2005:409316    CAPLUS  
DOCUMENT NUMBER:                      142:441894

TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases  
 INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf  
 PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztő Rt., Hung.  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
CN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510
PRIORITY APPLN. INFO.:			HU 2003-3584	A 20031030
			WO 2004-HU98	W 20041025
AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.				
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:263763 CAPLUS  
 DOCUMENT NUMBER: 140:399884  
 TITLE: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice  
 AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda  
 CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor

Neuroscience and Movement Disorders, The Graham Watts  
 Laboratory, University College London, London, WC1N  
 3BG, UK  
 SOURCE: Nature Medicine (New York, NY, United States) (2004),  
 10(4), 402-405  
 CODEN: NAMEFI; ISSN: 1078-8956  
 PUBLISHER: Nature Publishing Group  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal  
 neurodegenerative condition in which motoneurons of the spinal cord and  
 motor cortex die, resulting in progressive paralysis. This condition has  
 no cure and results in eventual death, usually within 1-5 yr of diagnosis.  
 Although the specific etiol. of ALS is unknown, 20% of familial  
 cases of the disease carry mutations in the gene encoding Cu/Zn superoxide  
 dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have  
 a phenotype and pathol. that are very similar to that seen in human  
 ALS patients. Here we show that treatment with arimoclomol, a  
 coinducer of heat shock proteins (HSPs), significantly delays disease  
 progression in mice expressing a SOD1 mutant in which glycine is  
 substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated  
 SOD1G93A mice show marked improvement in hind limb muscle function and  
 motoneuron survival in the later stages of the disease, resulting in a 22%  
 increase in lifespan. Pharmacol. activation of the heat shock response  
 may therefore be a successful therapeutic approach to treating ALS  
 , and possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	36.64	215.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

FILE 'REGISTRY' ENTERED AT 13:15:05 ON 17 NOV 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2  
 DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e arimoclomol

E1	1	ARIMIDS/BI
E2	1	ARIMOCLOM/BI
E3	1 -->	ARIMOCLOMOL/BI
E4	2	ARIMOL/BI
E5	2	ARIMOSA/BI
E6	1	ARIMOTO/BI
E7	130	ARIN/BI
E8	17	ARINA/BI
E9	1	ARINAE/BI
E10	1	ARINAMINE/BI
E11	4	ARINATE/BI
E12	56	ARINE/BI


=> s e3

L5 1 ARIMOCLOMOL/BI

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 289893-25-0 REGISTRY  
ED Entered STN: 21 Sep 2000  
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide (CA INDEX NAME)  
OTHER NAMES:  
CN Arimoclomol  
FS STEREOSEARCH  
MF C14 H20 Cl N3 O3  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, CA, CAPLUS, CBNB, EMBASE, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.  
Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e brx

E1	6	BRWR1/BI
E2	1	BRWY/BI
E3	32 -->	BRX/BI
E4	6	BRX1/BI
E5	2	BRX1A/BI
E6	2	BRX1B/BI

E7	6	BRXE/BI
E8	2	BRXE10/BI
E9	2	BRXE11/BI
E10	2	BRXE12/BI
E11	2	BRXE13/BI
E12	2	BRXE14/BI

=> e brx220

E1	2	BRX1A/BI
E2	2	BRX1B/BI
E3	0 -->	BRX220/BI
E4	6	BRXE/BI
E5	2	BRXE10/BI
E6	2	BRXE11/BI
E7	2	BRXE12/BI
E8	2	BRXE13/BI
E9	2	BRXE14/BI
E10	2	BRXE15/BI
E11	2	BRXE16/BI
E12	3	BRXE2/BI

=> s e3

L6	0	BRX220/BI
----	---	-----------

=> e brx

E1	6	BRWR1/BI
E2	1	BRWY/BI
E3	32 -->	BRX/BI
E4	6	BRX1/BI
E5	2	BRX1A/BI
E6	2	BRX1B/BI
E7	6	BRXE/BI
E8	2	BRXE10/BI
E9	2	BRXE11/BI
E10	2	BRXE12/BI
E11	2	BRXE13/BI
E12	2	BRXE14/BI

=> s e3

L7	32	BRX/BI
----	----	--------

=> d 17 1-32

L7 ANSWER 1 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 909311-85-9 REGISTRY  
 ED Entered STN: 02 Oct 2006  
 CN Glucagon-like peptide 1 [2-glycine,28-alanine,31-glycine] (human clone  
 WO2006/096515-SEQID-12) fusion protein with peptide (synthetic) fusion  
 protein with transferrin (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN	20: PN: WO2006096515 SEQID: 12 claimed protein
CN	BRX 0585
CN	GLP 1Tf
FS	PROTEIN SEQUENCE
MF	Unspecified
CI	MAN
SR	CA
LC	STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 2 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 889930-43-2 REGISTRY  
ED Entered STN: 28 Jun 2006  
CN Protein (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS  
RADIX)) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank ABG25053  
CN GenBank ABG25053 (Translated from: GenBank AY702649)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 3 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 889930-42-1 REGISTRY  
ED Entered STN: 28 Jun 2006  
CN DNA (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS RADIX)  
protein cDNA) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AY702649  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 4 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 889930-41-0 REGISTRY  
ED Entered STN: 28 Jun 2006  
CN Protein (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS  
RADIX) truncated isoform) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank ABG25052  
CN GenBank ABG25052 (Translated from: GenBank AY702648)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 5 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 889930-40-9 REGISTRY




ED Entered STN: 28 Jun 2006  
CN DNA (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS RADIX)  
protein truncated isoform cDNA plus 3'-flank) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN GenBank AY702648  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 850069-82-8 REGISTRY  
ED Entered STN: 09 May 2005  
CN Propanedioic acid, (6aS,11bR)-3-(acetyloxy)-7,11b-dihydrobenz[b]indeno[1,2-  
d]pyran-6a,9,10(6H)-triyl trimethyl ester (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 018  
FS STEREOSEARCH  
MF C30 H28 O15  
SR CA  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 688066-21-9 REGISTRY  
ED Entered STN: 01 Jun 2004  
CN Protein (Arabidopsis thaliana gene BRX) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 502923-63-9 REGISTRY  
ED Entered STN: 14 Apr 2003  
CN Amplex BRX (9CI) (CA INDEX NAME)  
ENTE An activator for pectinase mixture biopolishing agent (Color Center S.A., Spain)  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 496816-64-9 REGISTRY  
ED Entered STN: 03 Mar 2003  
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 51  
FS STEREOSEARCH  
MF C14 H20 Cl N3 O2 . C4 H4 O4  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-63-8  
CMF C14 H20 Cl N3 O2


Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 496816-62-7 REGISTRY  
ED Entered STN: 03 Mar 2003  
CN 3-Pyridinecarboximidoyl chloride, N-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 53  
FS STEREOSEARCH  
MF C14 H20 Cl N3 O2 . C4 H4 O4  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-61-6  
CMF C14 H20 Cl N3 O2


Absolute stereochemistry. Rotation (-).  
Double bond geometry as shown.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 412507-73-4 REGISTRY  
ED Entered STN: 08 May 2002  
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-a-05-0-UI EST (expressed sequence tag)) (CA INDEX NAME)  
OTHER NAMES:  
CN GenBank BM933144  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 12 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 392081-00-4 REGISTRY  
ED Entered STN: 13 Feb 2002  
CN DNA (human clone pDR2 gene BRX cDNA) (CA INDEX NAME)  
OTHER NAMES:  
CN 469: PN: WO2007132883 PAGE: 41 unclaimed DNA  
CN GenBank AF126008  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 388566-72-1 REGISTRY  
ED Entered STN: 31 Jan 2002  
CN BRX-Q (9CI) (CA INDEX NAME)  
ENTE An exerimental acrylamido-based ion-exchanger for protein chromatography  
(Bio-Rad Laboratories, Hercules, CA)  
MF Unspecified  
CI PMS, MAN  
PCT Manual registration  
SR CA  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 14 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 344670-25-3 REGISTRY  
ED Entered STN: 05 Jul 2001  
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-b-05-0-UI EST  
(expressed sequence tag)) (CA INDEX NAME)  
OTHER NAMES:  
CN GenBank BI133445  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 326984-24-1 REGISTRY

ED Entered STN: 13 Mar 2001  
CN DNA (Rattus norvegicus strain Sprague-Dawley clone  
UI-R-CV1-brx-h-03-0-UI EST (expressed sequence tag)) (9CI) (CA INDEX  
NAME)

OTHER NAMES:

CN 410: PN: US20050084872 TABLE: 9 claimed DNA  
CN GenBank BG373361  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 16 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 308063-34-5 REGISTRY \*

\* Use of this CAS Registry Number alone as a search term in other STN files may  
result in incomplete search results. For additional information, enter HELP  
RN\* at an online arrow prompt (=>).

ED Entered STN: 12 Dec 2000  
CN Rubber, butadiene, of cis-1,4-configuration (CA INDEX NAME)

OTHER NAMES:

CN Afdene Buna CB 11  
CN Ameripol CB  
CN Ameripol CB 200  
CN Ameripol CB 220  
CN Ameripol CB 221  
CN B 27  
CN B 27 (rubber)  
CN B 37  
CN B 37 (rubber)  
CN BCP 820  
CN BR 01  
CN BR 10  
CN BR 11  
CN BR 1208  
CN BR 1220  
CN BR 1220N  
CN BR 1220SG  
CN BR 1241  
CN BR 1280  
CN BR 130B  
CN BR 133P  
CN BR 150  
CN BR 150B  
CN BR 150L  
CN BR 153A  
CN BR 18  
CN BR 230  
CN BR 31  
CN BR 360L  
CN BR 40  
CN BR 51  
CN BR 60  
CN BR 700  
CN BR 700 (rubber)  
CN BR 701  
CN BR 730

CN BR 9000  
CN BR 9002  
CN BR 9002L  
CN BR 9004  
CN BR 9053  
CN BRX 5000  
CN Bud 1207  
CN Bud 1254  
CN Budene 1207  
CN Budene 1208  
CN Budene 1254  
CN Budene 1280  
CN Budene 207  
CN Buna CB 10  
CN Nipol BRX 5000

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

MF Unspecified  
CI MAN, CTS  
SR CA


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L7 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 289893-26-1 REGISTRY  
ED Entered STN: 21 Sep 2000  
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-  
piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-  
piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (salt) (9CI)  
OTHER NAMES:  
CN BRX 220  
FS STEREOSEARCH  
MF C14 H20 Cl N3 O3 . C4 H4 O4  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR,  
SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 289893-25-0  
CMF C14 H20 Cl N3 O3


Absolute stereochemistry.  
Double bond geometry unknown.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



8 REFERENCES IN FILE CA (1907 TO DATE)  
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 222187-17-9 REGISTRY  
ED Entered STN: 07 May 1999  
CN DNA (human clone 11.1/2.2 gene brx protein cDNA plus flanks) (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN DNA (human clone 11.1/2.2 gene brx nuclear receptor-binding auxiliary  
protein Brx cDNA plus flanks)  
CN DNA (human clone 11.1/2.2 gene brx putative rho guanine nucleotide  
exchange factor cDNA plus flanks)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L7 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 222187-15-7 REGISTRY  
ED Entered STN: 07 May 1999  
CN Protein (human clone 11.1/2.2 gene brx reduced) (9CI) (CA INDEX  
NAME)  
OTHER NAMES:  
CN Nuclear receptor-binding auxiliary protein Brx (human clone 11.1/2.2  
gene brx reduced)  
CN Putative Rho guanine nucleotide exchange factor (human clone 11.1/2.2  
gene brx reduced)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 215233-82-2 REGISTRY  
ED Entered STN: 08 Dec 1998  
CN Benzenecarboximidamide, N-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-  
N'-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 156

MF C20 H27 N3 O2 . Cl H  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL  
 CRN (774166-55-1)



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 210170-31-3 REGISTRY  
 ED Entered STN: 20 Aug 1998  
 CN Protein Brx (human) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE  
 MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 203805-20-3 REGISTRY  
 ED Entered STN: 08 Apr 1998  
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-  
 (CA INDEX NAME)

OTHER NAMES:

CN BRX 005  
 CN BRX 235  
 DR 191159-87-2  
 MF C14 H20 N4 O  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, PROUSDDR, SYNTHLINE, TOXCENTER,  
 USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 23 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 201556-27-6 REGISTRY  
ED Entered STN: 19 Feb 1998  
CN BRX 5 (primer) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 5  
ENTE A polyimide primer (Cytec)  
MF Unspecified  
CI PMS, MAN  
PCT Manual registration  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
4 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 24 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 181858-04-8 REGISTRY  
ED Entered STN: 10 Oct 1996  
CN RNA (measles virus strain Brx hemagglutinin gene  
fragment-complementary) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN GenBank Z80797  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 25 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 164479-36-1 REGISTRY  
ED Entered STN: 07 Jul 1995  
CN RNA (measles virus strain Brx nucleocapsid protein gene fragment)  
(9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Ribonucleic acid (measles virus strain Brx nucleocapsid protein gene  
fragment)  
OTHER NAMES:  
CN GenBank X84879  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 26 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 63394-00-3 REGISTRY \*

\* Use of this CAS Registry Number alone as a search term in other STN files may

result in incomplete search results. For additional information, enter HELP  
RN\* at an online arrow prompt (=>).

ED Entered STN: 16 Nov 1984

CN Rubber, butadiene (CA INDEX NAME)

OTHER NAMES:

CN 150L

CN 150L (rubber)

CN 60P

CN A 24

CN Alkadienes, rubber

CN Ameripol CB 441

CN Ameripol CB 880

CN Asadene

CN Asadene 35AS

CN Asadene 35NF

CN Asadene 55AS

CN Asadene 55NF

CN Asadene AS

CN Asadene NF 35A

CN Asadene NF 35AS

CN Asadene NF 50R

CN Asaprene 610AX

CN Asaprene 700A

CN Asaprene 720A

CN Asaprene 720AX

CN Asaprene 730AX

CN Asaprene 755A

CN Asaprene 756A

CN Asaprene 760A

CN Asaprene BR 730A

CN Austrapol 1220

CN Bayer 550

CN Bon RI 1

CN BR 02L

CN BR 02LL

CN BR 1200

CN BR 1202G

CN BR 1203

CN BR 1207

CN BR 1220L

CN BR 1220SU

CN BR 1250

CN BR 1441

CN BR 15HB

CN BR 200

CN BR 200 (rubber)

CN BR 23SH

CN BR 3505

CN BR 401

CN BR 401 (rubber)

CN BR 55F

CN BR 90

CN BR 900

CN BR 9001

CN BR 9073

CN BRX 3000

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

DR 62361-95-9, 51426-11-0, 178234-67-8

MF Unspecified

CI PMS, MAN, CTS

PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST,  
CIN, CSCHEM, TOXCENTER

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L7 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN

RN 3701-40-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[2-[4'-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]diazenyl]-, sodium salt (1:2) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[[4'-[(2-hydroxy-1-naphthalenyl)azo]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt (9CI)

CN C.I. Acid Red 99 (7CI)

CN C.I. Acid Red 99, disodium salt (8CI)

OTHER NAMES:

CN Acid Leather Red 2BG

CN Acid Red 99

CN Acidine Red RD

CN Airedale Red RM

CN Benzyl Fast Red 2BG

CN Best Acid Milling Red FRS

CN Brilliant Milling Red

CN C.I. 23285

CN Calcocid Milling Red RC

CN Coomassie Red R

CN Dynacid Red RS

CN Elite Fast Red BG

CN Elite Fast Red R

CN Elite Fast Red RS

CN Kayanol Red RS

CN Levanol Brilliant Red BB

CN Milling Fast Red R

CN Milling Fast Red RS

CN Milling Fast Red RX

CN Milling Red PRX

CN Multicuer Red BRX

CN Naphthalene Leather Red R

CN Optanol Red R

CN Pharmanil Red RB

CN Polar Red GBD

CN Polar Red R

CN Shikiso Acid Red RS

CN Sulfonine Red RS

CN Suminol Milling Red GRS

CN Suminol Red RS

CN Supranol Fast Red RX

CN Takaoka Acid Red RS

CN Triacid Fast Red GRS

MF C34 H26 N4 O8 S2 . 2 Na


LC STN Files: CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, RTECS\*, TOXCENTER,  
USPATFULL, USPATOLD

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (25317-42-4)




●2 Na

21 REFERENCES IN FILE CA (1907 TO DATE)  
 21 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 2241-61-4 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,  
 tetraacetate, (6aS,11bR)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,  
 tetraacetate (7CI)  
 CN Benz[b]indeno[2,1-d]pyran-3,6a,9,10(6H)-tetrol, 7,10b-dihydro-,  
 tetraacetate, (6aS-cis)-  
 OTHER NAMES:  
 CN BRX 019  
 CN Tetraacetylbrazililn  
 FS STEREOSEARCH  
 MF C24 H22 O9  
 LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, MEDLINE,  
 PROUDDR, SYNTHLINE, TOXCENTER  
 (\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN

RN 1658-56-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1-Naphthalenesulfonic acid, 4-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-,  
sodium salt (1:1) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1-Naphthalenesulfonic acid, 4-[(2-hydroxy-1-naphthalenyl)azo]-, monosodium  
salt (9CI)

CN C.I. Acid Red 88, monosodium salt (8CI)

OTHER NAMES:

CN 11391 Red

CN 2-Naphthol Red J

CN Acid Cardinal G

CN Acid Fast Red A

CN Acid Leather Red ROC

CN Acid Red 88

CN Acid Red A

CN Acid Red A (Chinese)

CN Acid Red AV

CN Acid Red G

CN Acid Rose AV

CN Acid Scarlet G

CN Airedale Red A

CN Amacid Fast Red A

CN Ambicid Fast Red E

CN Anadurm Red A-ROC

CN Anthrosin BRX

CN Apollo Acid Rocceline

CN Atul Acid Fast Red A

CN Azo Acid Red GS

CN Basacid Red 340

CN Benzyl Red ROC

CN Benzyl Red S

CN Brasilan Red S

CN Bucacid Fast Red A

CN C.I. 15620

CN C.I. Acid Red 88

CN Calcocid Fast Red A

CN Cavalene Red A

CN Colacid Red AV

CN Colocid Fast Red A

CN Conacid Red MM

CN Daedo Acid Roccelline NS

CN Dai-ei Roccelline

CN Derma Fur Red R 150

CN Diacid Red A

CN Dinacid Fast Red A

CN Dyacid Red J

CN Dycosacid Red A

CN Eniacid Fast Red A

CN Eriosin Roccelline

CN Eriosin Roccelline SS

CN Ext D and C Red No. 8

CN Fabracid Red S-A

CN Fast Acid Red G

CN Fast Red A


CN Fast Red A (acid dye)

CN Fast Red AE

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

DR 163442-07-7, 39309-87-0

MF C20 H14 N2 O4 S . Na  
 CI COM  
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS,  
 CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DETHERM\*, IFICDB, IFIPAT, IFIUDB,  
 MEDLINE, MSDS-OHS, PIRA, PROMT, RTECS\*, TOXCENTER, USPAT2, USPATFULL,  
 USPATOLD  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (18268-54-7)



● Na

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

429 REFERENCES IN FILE CA (1907 TO DATE)  
 9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 429 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 1326-85-8 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN C.I. Sulphur Black 2 (8CI, 9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN C.I. 53195  
 CN C.I. Sulfur Black 2  
 CN Calcogene Black 2R-CF  
 CN Calcogene Black RB-CF  
 CN Diresul Black 2R  
 CN Diresul Black 3R  
 CN Diresul Black EV-PL  
 CN Eclipse Deep Black BG  
 CN Fenoxyl Black 2R  
 CN Katigen Deep Black RRND-CF  
 CN Kayaku Sulphur Black BRX  
 CN Mitsui Sulphur Black ABR  
 CN Mitsui Sulphur Black BBRO  
 CN Mitsui Sulphur Black BR  
 CN Mitsui Sulphur Black R

CN Mitsui Sulphur Black RC  
 CN Nissen Black BRX  
 CN Sodyesul Black MCF  
 CN Solfo Black 3R  
 CN Solfo Black R  
 CN Sulfanol Black 2R  
 CN Sulfogene Carbon 4RCF  
 CN Sulfogene Carbon MCF  
 CN Sulfogene Carbon Supra CF Grains  
 CN Sulfogene Carbon T  
 CN Sulfogene Grey H1A grai  
 CN Sulfur Black 2  
 CN Sulfur Black 2RD  
 CN Sulfur Black 4RD  
 CN Sulfur Black DR  
 CN Sulfur Black RND  
 CN Sulphol Black BSP  
 CN Sulphol Black BSP Paste  
 CN Sulphol Black No. 44  
 CN Sulphol Black PG  
 CN Sulphol Black PXR Ex. Conc  
 CN Sulphol Black PXR Paste  
 CN Sulphol Black RS Grains  
 CN Sulphol Liquid Black QR  
 CN Sulphur Black 2  
 CN Thionol Black R  
 DEF This substance is identified in the COLOUR INDEX by Colour Index  
 Constitution Number, C.I. 53195.  
 MF Unspecified  
 CI MAN  
 LC STN Files: CA, CAPLUS, CHEMCATS, CHEMLIST, TOXCENTER, USPAT2, USPATFULL  
 Other Sources: NDSL\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 11 REFERENCES IN FILE CA (1907 TO DATE)  
 11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 1064-48-8 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-(4-nitrophenyl)diazenyl]-6-(2-phenyldiazenyl)-, sodium salt (1:2) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[(4-nitrophenyl)azo]-6-(phenylazo)-, disodium salt (9CI)  
 CN Amido Black 10B (6CI)  
 OTHER NAMES:  
 CN Acid Black 1  
 CN Acid Black 10A  
 CN Acid Black 10B  
 CN Acid Black 10BA  
 CN Acid Black 10BN  
 CN Acid Black 10BX  
 CN Acid Black 12B  
 CN Acid Black 4BN  
 CN Acid Black 4BNU  
 CN Acid Black 8GB  
 CN Acid Black Base M  
 CN Acid Black BRX  
 CN Acid Black BX

CN Acid Black H  
 CN Acid Black JVS  
 CN Acid Blue Black  
 CN Acid Blue Black 10B  
 CN Acid Blue Black 10BX  
 CN Acid Blue Black B  
 CN Acid Blue Black BG  
 CN Acid Blue Black Double 600  
 CN Acid Blue Black Sh  
 CN Acid Leather Blue IGW  
 CN Acid Leather Dark Blue G  
 CN Acid Leather Fast Blue Black G  
 CN Acidal Black 10B  
 CN Acidal Black MV  
 CN Acidal Navy Blue 3BR  
 CN Aciderm Black E 10B  
 CN Acilan Black 10B  
 CN Airedale Black 2BG  
 CN Amacid Black 10BR  
 CN Amide Black 10B  
 CN Amido Black  
 CN Amido Blue Black 12B  
 CN Apollo Acid Blue Black 10B  
 CN Atul Acid Black 10BX  
 CN Atul Acid Black BX  
 CN Azanol Fast Acid Black 10B  
 CN Azo Dark Blue C 2B  
 CN Azo Dark Blue HR  
 CN Azo Dark Blue S  
 CN Azo Dark Blue SH  
 CN Best Acid Dark Blue B  
 CN Black 401  
 CN Blue Black 12B  
 CN Blue Black SX  
 CN Borunil Grey A 10B

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

DR 12042-02-3, 68417-62-9, 84842-81-9, 86923-11-7, 31258-44-3

MF C22 H16 N6 O9 S2 . 2 Na

CI COM


LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA,  
 CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, IFICDB,  
 IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, RTECS\*, TOXCENTER, USPAT2,  
 USPATFULL, USPATOLD

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (3121-74-2)





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

925 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
926 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2008 ACS on STN

RN 147-14-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Copper, [29H,31H-phthalocyaninato(2-)-  
κN29,κN30,κN31,κN32]-, (SP-4-1)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 29H,31H-Phthalocyanine, copper complex

CN 29H,31H-Phthalocyanine, copper deriv.

OTHER NAMES:

CN (Phthalocyaninato)copper

CN α-Copper phthalocyanine

CN α-Copper phthalocyanine blue

CN α-Phthalocyanine blue

CN β-Copper phthalocyanine blue

CN β-Phthalocyanine blue

CN ε-Copper phthalocyanine

CN 127EPS

CN 405D

CN 7075M

CN 79S26C

CN 79S26C chip

CN Accosperse Cyan Blue GT

CN Acnalin Supra Blue G

CN Acramin Blue F 3G

CN Akrochem 626

CN Aqualine Blue

CN Aquis BW 3571

CN Arlocyanine Blue PS

CN Aztech Chemisperse Cyan 1541

CN B 4G-KR

CN B 702W

CN B 705H

CN B 736

CN B 8M25

CN Bahama Blue BC

CN Bahama Blue BNC

CN Bahama Blue Lake NCF

CN Bahama Blue WD

CN Bermuda Blue

CN BFD 1121

CN BGS 1

CN BGSG-C

CN BL 1531

CN Blue 7110V

CN Blue GLA

CN Blue GLA-SD

CN Blue GLSM

CN Blue Microdis

CN Blue phthalocyanine α-form

CN Blue pigment

CN Blue Toner GTNF

CN BRS 1

CN BRX

CN BT 4651

CN C.I. 74160  
CN C.I. Pigment Blue 15  
CN C.I. Pigment Blue 15:1

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

DR 807622-86-2, 819860-69-0, 819860-85-0, 878390-73-9, 924902-00-1,  
12767-67-8, 10482-39-0, 11097-56-6, 11129-84-3, 177529-54-3, 177646-05-8,  
158853-86-2, 172308-31-5, 172826-46-9, 53802-06-5, 57916-96-8, 57425-52-2,  
55819-49-3, 59518-91-1, 59966-88-0, 64333-57-9, 95660-31-4, 95917-74-1,  
96024-35-0, 104921-99-5, 51331-32-9, 115284-42-9, 60880-51-5, 60937-79-3,  
61489-66-5, 61489-77-8, 61537-10-8, 109675-77-6, 109766-95-2, 66121-19-5,  
37223-81-7, 69431-77-2, 78170-27-1, 78413-59-9, 85255-95-4, 85256-77-5,  
92909-14-3, 90452-20-3, 34567-54-9, 39378-75-1, 39473-10-4, 53028-77-6,  
175386-67-1, 184007-78-1, 209343-48-6, 211564-97-5, 211925-80-3,  
213190-86-4, 244244-86-8, 345338-75-2, 392718-62-6, 681847-78-9

MF C32 H16 Cu N8

CI CCS, COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAOLD,  
CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM\*,  
EMBASE, GMELIN\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*,  
MSDS-OHS, PIRA, PROMT, RTECS\*, SPECINFO, TOXCENTER, USPAT2, USPATFULL,  
USPATOLD


(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17797 REFERENCES IN FILE CA (1907 TO DATE)  
 1297 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 17840 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 134 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
85.59	300.80

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-6.40

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 13:20:23 ON 17 NOV 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Nov 2008 VOL 149 ISS 21  
 FILE LAST UPDATED: 16 Nov 2008 (20081116/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s (15 of 17 or arimoclomol) and (aml or sclerosis)  
 MISSING OPERATOR L5 OF

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s (15 or 17 or arimoclomol) and (aml or sclerosis)  
 10 L5

19197 L7  
9 ARIMOCLOMOL  
8038 AML  
253 AMLS  
8079 AML

(AML OR AMLS)

33016 SCLEROSIS  
30 SCLEROSES  
33031 SCLEROSIS

(SCLEROSIS OR SCLEROSES)

L8 11 (L5 OR L7 OR ARIMOCLOMOL) AND (AML OR SCLEROSIS)

=> d l8 ibib abs 1-11

L8 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1320737 CAPLUS

TITLE: Late stage treatment with arimoclomol delays  
disease progression and prevents protein aggregation  
in the SOD1G93A mouse model of ALS

AUTHOR(S): Kalmar, Bernadett; Novoselov, Sergey; Gray, Anna;  
Cheetham, Michael E.; Margulis, Boris; Greensmith,  
Linda

CORPORATE SOURCE: Institute of Neurology, University College London,  
London, UK

SOURCE: Journal of Neurochemistry (2008), 107(2), 339-350  
CODEN: JONRA9; ISSN: 0022-3042

PUBLISHER: Wiley-Blackwell

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motoneuron degeneration, resulting in muscle paralysis and death, typically within 1-5 years of diagnosis. Although the pathogenesis of ALS remains unclear, there is evidence for the involvement of proteasome dysfunction and heat shock proteins in the disease. We have previously shown that treatment with a co-inducer of the heat shock response called arimoclomol is effective in the SODG93A mouse model of ALS, delaying disease progression and extending the lifespan of SODG93A mice. However, this previous study only examined the effects arimoclomol when treatment was initiated in pre- or early symptomatic stages of the disease. Clearly, to be of benefit to the majority of ALS patients, any therapy must be effective after symptom onset. In order to establish whether post-symptomatic treatment with arimoclomol is effective, in this study we carried out a systematic assessment of different treatment regimes in SODG93A mice. Treatment with arimoclomol from early (75 days) or late (90 days) symptomatic stages significantly improved muscle function. Treatment from 75 days also significantly increased the lifespan of SODG93A mice, although treatment from 90 days has no significant effect on lifespan. The mechanism of action of arimoclomol involves potentiation of the heat shock response, and treatment with arimoclomol increased Hsp70 expression. Interestingly, this up-regulation in Hsp70 was accompanied by a decrease in the number of ubiquitinpos. aggregates in the spinal cord of treated SODG93A mice, suggesting that arimoclomol directly effects protein aggregation and degradation

L8 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:918262 CAPLUS

DOCUMENT NUMBER: 149:258394

TITLE: Arimoclomol at dosages up to 300 Mg/day is  
well tolerated and safe in amyotrophic lateral  
sclerosis

AUTHOR(S): Cudkowicz, Merit E.; Shefner, Jeremy M.; Simpson, Elizabeth; Grasso, Daniela; Yu, Hong; Zhang, Hui; Shui, Amy; Schoenfeld, David; Brown, Robert H.; Wieland, Scott; Barber, Jack R.

CORPORATE SOURCE: NORTHEAST ALS CONSORTIUM, Neurology Clinical Trials Unit, Massachussets General Hospital, Charlestown, MA, 02129, USA

SOURCE: Muscle & Nerve (2008), 38(1), 837-844  
CODEN: MUNEDE; ISSN: 0148-639X

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic anal. Participants who completed 12 wk of treatment could enroll in a 6-mo open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacol. exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:223578 CAPLUS

DOCUMENT NUMBER: 148:269430

TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease

INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas

PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.

SOURCE: PCT Int. Appl., 127pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
WO 2008021210	A3	20081030		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,			

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  
 US 20080044390 A1 20080221 US 2007-891552 20070810  
 PRIORITY APPLN. INFO.: US 2006-837448P P 20060811  
 US 2007-898479P P 20070131  
 US 2007-925777P P 20070423  
 US 2007-958832P P 20070709

AB The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected, selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small mols. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.

L8 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1424894 CAPLUS  
 DOCUMENT NUMBER: 148:492092  
 TITLE: Heat shock proteins and protection of the nervous system  
 AUTHOR(S): Brown, Ian R.  
 CORPORATE SOURCE: Center for the Neurobiology of Stress, University of Toronto at Scarborough, Toronto, ON, Can.  
 SOURCE: Annals of the New York Academy of Sciences (2007), 1113(Stress Responses in Biology and Medicine), 147-158  
 CODEN: ANYAA9; ISSN: 0077-8923  
 PUBLISHER: Blackwell Publishing, Inc.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. Manipulation of the cellular stress response offers strategies to protect brain cells from damage induced by ischemia and neurodegenerative diseases. Overexpression of Hsp70 reduced ischemic injury in the mammalian brain. Investigation of the domains within Hsp70 that confers ischemic neuroprotection revealed the importance of the carboxyl-terminal domain. Arimoclomol, a coinducer of heat shock proteins, delayed progression of amyotrophic lateral sclerosis (ALS) in a mouse model in which motor neurons in the spinal cord and motor cortex degenerate. Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, induced expression of a set of Hsps in differentiated neurons grown in tissue culture. Heat shock "preconditioning" protected the nervous system at the functional level of the synapse and selective overexpression of Hsp70 enhanced the level of synaptic protection. Following hyperthermia, constitutively expressed Hsc70 increased in synapse-rich areas of the brain where it assoc. with Hsp40 to form a complex that can refold denatured proteins. Stress tolerance in neurons is not solely dependent on their own Hsps but can be supplemented by Hsps from adjacent glial cells. Hence, application of exogenous Hsps at neural injury sites is an effective strategy to maintain neuronal viability.

REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1207486 CAPLUS

DOCUMENT NUMBER: 147:466838

TITLE: Identifying signal transduction pathways that mediate nervous system plasticity by gene expression profiling and the selection of pathway modulators for therapeutic use

INVENTOR(S): Sur, Mriganka; Tropea, Daniela; Kreiman, Gabriel

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 407pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120847	A2	20071025	WO 2007-US9172	20070412
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-792275P P 20060414

AB Methods for identifying genes and pathways involved in neuronal plasticity by anal. of the effects of deprivation and stimulation on patterns of gene expression in nervous tissue are described. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacol. agents that modify plasticity and candidate agents modifying neuronal plasticity are identified. The invention also identifies biol. pathways that are enriched in the products of genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The methods and compns. may be administered to a subject suffering from damage to the nervous system or from a neuropsychiatric disorder in order to enhance recovery, reorganization, or function of the nervous system. The methods optionally include administering a proteolysis-enhancing agent to the subject.

L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:711978 CAPLUS

DOCUMENT NUMBER: 147:377138

TITLE: Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotrophic lateral sclerosis

AUTHOR(S): Bedlack, Richard S.; Traynor, Bryan J.; Cudkowicz, Merit E.

CORPORATE SOURCE: Duke University Medical Center, Durham, NC, USA

SOURCE: Expert Opinion on Emerging Drugs (2007), 12(2), 229-252

CODEN: EOEDA3

PUBLISHER: Informa Healthcare

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. It has been > 130 years since the first description of the upper and lower motor neuron disease called amyotrophic lateral sclerosis (ALS). Sadly, there has been little change in the long interval over which this disease is diagnosed, or in its poor prognosis. Significant gains have been made, however, in understanding its pathophysiol. and in symptomatic care. Disease-causing mutations have been identified and used to create animal models. Other identified mutations may increase susceptibility and cause disease only in a particular environment and at a particular age. A number of 'downstream' mol. pathways have been implicated, including transcriptional disturbances, protein aggregation, excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, cytoskeletal and axonal transport derangements, growth factor dysregulation and apoptosis. This knowledge has led to an impressive pipeline of candidate therapies that offer hope for finally being able to alter ALS disease progression. These are described and prioritized herein, and suggestions are offered for efficiently sifting through them.

REFERENCE COUNT: 148 THERE ARE 148 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:598700 CAPLUS

DOCUMENT NUMBER: 145:499471

TITLE: Neuroprotective agents for clinical trials in ALS

AUTHOR(S): Traynor, B. J.; Bruijn, L.; Conwit, R.; Beal, F.; O'Neill, G.; Fagan, S. C.; Cudkowicz, M. E.

CORPORATE SOURCE: Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

SOURCE: Neurology (2006), 67(1), 20-27

CODEN: NEURAI; ISSN: 0028-3878

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Background: Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest. Objective: To identify potential neuroprotective agents for testing in phase III clin. trials and to outline which data need to be collected for each drug. Methods: The authors identified 113 compds. by inviting input from academic clinicians and researchers and via literature review to identify agents that have been tested in ALS animal models and in patients with ALS. The list was initially narrowed to 24 agents based on an evaluation of scientific rationale, toxicity, and efficacy in previous animal and human studies. These 24 drugs underwent more detailed pharmacol. evaluation. Results: Twenty drugs were selected as suitable for further development as treatments for patients with ALS. Talampanel and tamoxifen have completed early phase II trials and have demonstrated preliminary efficacy. Other agents (ceftriaxone, minocycline, ONO-2506, and IGF-1 polypeptide) are already in phase III trials involving large nos. of patients with ALS. Remaining agents (AEOL 10150, arimoclomol, celastrol, coenzyme Q10, copaxone, IGF-1-viral delivery, memantine, NAALADase inhibitors, nimesulide, scriptaid, sodium phenylbutyrate, thalidomide, trehalose) require addnl. preclin. animal data, human toxicity and pharmacokinetic data including CNS penetration prior to proceeding to large scale phase III human testing. Further development of riluzole analogs should be considered. Conclusions: Several potential neuroprotective compds., representing a wide range of mechanisms, are available and merit further investigation in ALS.

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS



## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:409316 CAPLUS

DOCUMENT NUMBER: 142:441894

TITLE: Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases

INVENTOR(S): Greensmith, Linda; Burnstock, Geoffrey; Urbanics, Rudolf

PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztő Rt., Hung.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041965	A1	20050512	WO 2004-HU98	20041025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285343	A1	20050512	AU 2004-285343	20041025
CA 2544332	A1	20050512	CA 2004-2544332	20041025
EP 1696922	A1	20060906	EP 2004-791657	20041025
EP 1696922	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015625	A	20061212	BR 2004-15625	20041025
CN 1901913	A	20070124	CN 2004-80039619	20041025
JP 2007509920	T	20070419	JP 2006-537449	20041025
AT 409038	T	20081015	AT 2004-791657	20041025
MX 2006PA04814	A	20061211	MX 2006-PA4814	20060428
NO 2006002401	A	20060727	NO 2006-2401	20060526
IN 2006KN01464	A	20070504	IN 2006-KN1464	20060530
US 20080039497	A1	20080214	US 2007-582124	20070510
PRIORITY APPLN. INFO.:			HU 2003-3584	A 20031030
			WO 2004-HU98	W 20041025

AB The invention relates to the use of a chemical substance selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxyl]-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixts. of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compds. in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:263763 CAPLUS

DOCUMENT NUMBER: 140:399884

TITLE: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.;  
Riddoch-Contreras, Joanna; Burnstock, Geoffrey;  
Greensmith, Linda

CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery,  
Institute of Neurology, Sobell Department of Motor  
Neuroscience and Movement Disorders, The Graham Watts  
Laboratory, University College London, London, WC1N  
3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) (2004),  
10(4), 402-405  
CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative  
condition in which motoneurons of the spinal cord and motor cortex die,  
resulting in progressive paralysis. This condition has no cure and  
results in eventual death, usually within 1-5 yr of diagnosis. Although  
the specific etiol. of ALS is unknown, 20% of familial cases of the  
disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1  
(SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype  
and pathol. that are very similar to that seen in human ALS patients.  
Here we show that treatment with arimoclomol, a coinducer of  
heat shock proteins (HSPs), significantly delays disease progression in  
mice expressing a SOD1 mutant in which glycine is substituted with alanine  
at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice  
show marked improvement in hind limb muscle function and motoneuron  
survival in the later stages of the disease, resulting in a 22% increase  
in lifespan. Pharmacol. activation of the heat shock response may  
therefore be a successful therapeutic approach to treating ALS, and  
possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:401127 CAPLUS

DOCUMENT NUMBER: 75:1127

ORIGINAL REFERENCE NO.: 75:187a,190a

TITLE: Histochemistry of myelin. XII. Anionic staining of  
myelin basic proteins for histology, electrophoresis,  
and electron microscopy

AUTHOR(S): Adams, Colin W. M.; Bayliss, Olga B.; Hallpike, J. F.;  
Turner, D. R.

CORPORATE SOURCE: Med. Sch., Guy's Hosp., London, UK

SOURCE: Journal of Neurochemistry (1971), 18(3), 389-94  
CODEN: JONRA9; ISSN: 0022-3042

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Phosphotungstic acid hematoxylin, trypan blue, and amido black techniques  
were developed as anionic dye methods for staining myelin basic proteins.  
All methods displayed central and peripheral nervous system myelin in  
histochem. preps. and stained brain basic proteins in electrophoretic  
polyacrylamide gels: phosphotungstic acid hematoxylin appeared to be the  
most selective of these techniques. Electron photomicrographs of  
peripheral nerve stained by phosphotungstic acid hematoxylin showed that  
the major part of myelin basic protein is located in the period dense  
line. The basic proteins stained by phosphotungstic acid hematoxylin  
showed an early loss in rat sciatic nerve undergoing Wallerian  
degeneration and had completely disappeared from the center of 20 plaques  
of multiple sclerosis.

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1959:73788 CAPLUS  
DOCUMENT NUMBER: 53:73788  
ORIGINAL REFERENCE NO.: 53:13384b  
TITLE: Histochemistry and classification of the  
Pelizaeus-Merzbacher disease  
AUTHOR(S): Seitelberger, Franz  
CORPORATE SOURCE: Univ. Vienna, Munich, Germany  
SOURCE: Cerebral Lipidoses (J. N. Cumings and A Lowenthal,  
editors. Charles C Thomas, publisher) (1957), Volume  
Date 1955, (Symposium, Antwerp), 92-7  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
AB Review with reference.

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	8	FEB 10	COMPENDEX reloaded and enhanced
NEWS	9	FEB 11	WTEXTILES reloaded and enhanced
NEWS	10	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants



New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e ariclomol

E1	1	ARICIRESIN/BI
E2	1	ARICIRESINOL/BI
E3	0 -->	ARICLOMOL/BI
E4	2	ARICOL/BI
E5	2	ARICOLA/BI
E6	2	ARICRKSARI/BI
E7	3	ARICYL/BI
E8	9	ARID/BI
E9	2	ARID1/BI
E10	2	ARID1A/BI
E11	2	ARID1B/BI
E12	8	ARID2/BI

=> e arimoclomol

E1	1	ARIMIDS/BI
E2	1	ARIMOCLOM/BI
E3	1 -->	ARIMOCLOMOL/BI
E4	2	ARIMOL/BI
E5	2	ARIMOSA/BI
E6	1	ARIMOTO/BI
E7	130	ARIN/BI
E8	17	ARINA/BI
E9	13	ARINAE/BI
E10	1	ARINAMINE/BI
E11	4	ARINATE/BI
E12	56	ARINE/BI

=> s e3


L1 1 ARIMOCLOMOL/BI

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 289893-25-0 REGISTRY  
ED Entered STN: 21 Sep 2000  
CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide (CA INDEX NAME)  
OTHER NAMES:  
CN Arimoclomol  
FS STEREOSEARCH  
MF C14 H20 Cl N3 O3  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, CA, CAPLUS, CBNB, EMBASE, IMSRESEARCH, PHAR, PROUDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry unknown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

14 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus embase biosis  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
12.68	13.88

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:04:53 ON 22 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:04:53 ON 22 APR 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:04:53 ON 22 APR 2009  
Copyright (c) 2009 The Thomson Corporation

=> s l1 or (arimoclomol or (brx (a) 220)  
UNMATCHED LEFT PARENTHESIS 'OR (ARIMOCLOMO'  
The number of right parentheses in a query must be equal to the  
number of left parentheses.

=> s l1 or (arimoclomol or (brx (a) 220))  
L2 80 L1 OR (ARIMOCLOMOL OR (BRX (A) 220))

=> dup rem l2  
PROCESSING COMPLETED FOR L2  
L3 62 DUP REM L2 (18 DUPLICATES REMOVED)

=> s l3 and @py<=2004  
'2004' NOT A VALID FIELD CODE  
'2004' NOT A VALID FIELD CODE  
'2004' NOT A VALID FIELD CODE  
L4 0 L3 AND @PY<=2004

=> s l3 and py<=2004  
L5 14 L3 AND PY<=2004

=> d l5 ibib abs 1-14

L5 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:263763 CAPLUS  
DOCUMENT NUMBER: 140:399884  
TITLE: Treatment with arimoclomol, a coinducer of

heat shock proteins, delays disease progression in ALS mice

AUTHOR(S): Kieran, Dairin; Kalmar, Bernadett; Dick, James R. T.; Riddoch-Contreras, Joanna; Burnstock, Geoffrey; Greensmith, Linda

CORPORATE SOURCE: The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, The Graham Watts Laboratory, University College London, London, WC1N 3BG, UK

SOURCE: Nature Medicine (New York, NY, United States) ( 2004), 10(4), 402-405  
CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motoneurons of the spinal cord and motor cortex die, resulting in progressive paralysis. This condition has no cure and results in eventual death, usually within 1-5 yr of diagnosis. Although the specific etiol. of ALS is unknown, 20% of familial cases of the disease carry mutations in the gene encoding Cu/Zn superoxide dismutase-1 (SOD1). Transgenic mice overexpressing human mutant SOD1 have a phenotype and pathol. that are very similar to that seen in human ALS patients. Here we show that treatment with arimoclomol, a coinducer of heat shock proteins (HSPs), significantly delays disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 (SOD1G93A). Arimoclomol-treated SOD1G93A mice show marked improvement in hind limb muscle function and motoneuron survival in the later stages of the disease, resulting in a 22% increase in lifespan. Pharmacol. activation of the heat shock response may therefore be a successful therapeutic approach to treating ALS, and possibly other neurodegenerative diseases.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:100113 CAPLUS

DOCUMENT NUMBER: 141:17416

TITLE: The effect of treatment with BRX-220, a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury

AUTHOR(S): Kalmar, B.; Greensmith, L.; Malcangio, M.; McMahon, S. B.; Csermely, P.; Burnstock, G.

CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK

SOURCE: Experimental Neurology (2003), 184(2), 636-647  
CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, we examined the effect BRX-220, a co-inducer of heat shock proteins, in injury-induced peripheral neuropathy. Following sciatic nerve injury in adult rats and treatment with BRX-220, the following features of the sensory system were studied: (a) expression of calcitonin gene-related peptide (CGRP); (b) binding of isolectin B4 (IB4) in dorsal root ganglia (DRG) and spinal cord; (c) stimulation-evoked release of substance P (SP) in an in vitro spinal cord preparation and (d) nociceptive responses of partially denervated rats. BRX-220 partially reverses

axotomy-induced changes in the sensory system. In vehicle-treated rats there is a decrease in IB4 binding and CGRP expression in injured neurons, while in BRX-220-treated rats these markers were better preserved. Thus,  $7.0 \pm 0.6\%$  of injured DRG neurons bound IB4 in vehicle-treated rats compared to  $14.4 \pm 0.9\%$  in BRX-220-treated animals. Similarly,  $4.5 \pm 0.5\%$  of DRG neurons expressed CGRP in the vehicle-treated group, whereas  $9.0 \pm 0.3\%$  were pos. in the BRX-220-treated group. BRX-220 also partially restored SP release from spinal cord sections to elec. stimulation of primary sensory neurons. Behavioral tests carried out on partially denervated animals showed that BRX-220 treatment did not prevent the emergence of mech. or thermal hyperalgesia. However, oral treatment for 4 wk lead to reduced pain-related behavior suggesting either slowly developing analgesic actions or enhancement of recovery processes. Thus, the morphol. improvement seen in sensory neuron markers was accompanied by restored functional activity. Therefore, treatment with BRX-220 promotes restoration of morphol. and functional properties in the sensory system following peripheral nerve injury.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587024 CAPLUS

DOCUMENT NUMBER: 138:130888

TITLE: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models

AUTHOR(S): Kurthy, Maria; Mogyrosi, Tamas; Nagy, Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi, Laszlo; Biro, Katalin

CORPORATE SOURCE: Biorex Research and Development Company, Veszprem, Hung.

SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 482-489

CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bimocloamol (BML), a symptomatic antidiabetic agent, was developed by Biorex R&D Co. to treat diabetic neuropathy and retinopathy. BRX-220, an orally active member of the BRX family, was developed to treat diabetic complications and insulin resistance (IR) as a follow-up compound. The effect of BRX-220 on peripheral neuropathy was examined in rats with diabetes (type 1) induced by administration of a  $\beta$ -cell toxin, streptozotocin (STZ, 45 mg/kg iv). Nerve functions were evaluated by electrophysiol. measurements of muscle motor and sensory nerve conduction velocities (MNCV and SNCV, resp.). MNCV and SNCV decreased in diabetic rats by 25%. A 1-mo preventive treatment with BRX-220 (2.5, 5, 10, and 20 mg/kg po) dose-dependently improved diabetes-related deficits in MNCV (51.3, 71.3, 86.1, and 91.3%) and SNCV (48.9, 68.5, 86.1, and 93.2%). Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes). Severe IR was detected in STZ diabetic and ZDF rats. This resistance was significantly reduced by BRX-220 treatment.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587016 CAPLUS



DOCUMENT NUMBER: 138:130887  
TITLE: Comparison of the extrapancreatic action of  
BRX-220 and pioglitazone in the  
high-fat diet-induced insulin resistance  
AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyorosi, T.; Nagy,  
Karoly; Demcakova, Edita; Ukropec, Jozef; Koranyi,  
Laszlo; Klimes, Iwar  
CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute  
of Experimental Endocrinology, Slovak Academy of  
Sciences, Bratislava, SK-83306, Slovakia  
SOURCE: Annals of the New York Academy of Sciences (  
2002), 967(Lipids and Insulin Resistance),  
424-430  
CODEN: ANYAA9; ISSN: 0077-8923  
PUBLISHER: New York Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A new Biorex mol., BRX-220, was shown to be effective  
in animal models of diabetic neuro- and retinopathy. Recent in vitro  
studies showed that it might also have an insulin-sensitizing action.  
Therefore, the effect of BRX-220 on insulin  
sensitivity was compared with the action of pioglitazone (PGZ) in high fat  
(HF) diet-induced insulin resistance (IR) of rats. Methods-Male Wistar  
rats were fed for 3 wk a standard chow (PD) or the HF (70-cal%) diet. The  
HF-fed rats were also given daily BRX-220 (20 mg/kg  
BW) or PGZ (6 mg/kg BW) by gavage. In vivo insulin action was assessed by  
the euglycemic hyperinsulinemic clamp. Glucose, insulin, FFA,  
triglyceride (TG), and glycerol levels in blood were also measured, as  
well as tissue TG content. Results-Increased levels of fed TG in  
circulation after HF diet (PD: 2.0 vs. HF: 5.0 mmol/L) were partially corrected  
by BRX-220 (HF+BRX: 3.8) and normalized by PGZ  
(HF+PGZ: 2.6). Both mols. prevented the increase in fed serum FFA levels  
after HF diet (PD: 0.5; HF: 1.8±0.2 mmol/L), with a more pronounced  
effect of PGZ (HF+BRX: 1.2; HF+PGZ: 0.7). Tissue TG levels increased  
significantly in response to HF feeding in both liver (HF: 16; PD: 6.4  
µmol/g) and skeletal muscle (HF: 7.7; PD: 2.4). This increase was  
completely normalized by both agents in the liver (HF+BRX: 8.8; HF+PGZ:  
8.8), and only partially in the skeletal muscles. HF diet-induced in vivo  
IR (PD: 25.4; HF: 15.7 mg/kg/min) was significantly reduced by BRX  
-220 (HF+BRX: 18.7) and PGZ (HF+PGZ: 22.8) treatment.  
Conclusions-(1) Subchronic administration of BRX-220  
leads to an improvement of in vivo insulin action. (2) This  
insulin-sensitizing effect is, however, not as pronounced as that of PGZ.  
(3) It is accompanied by a decrease of circulating TG and FFA levels in  
the postprandial state and (4) by lower TG content in liver and skeletal  
muscle.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:496814 CAPLUS  
DOCUMENT NUMBER: 137:362925  
TITLE: Upregulation of Heat Shock Proteins Rescues  
Motoneurons from Axotomy-Induced Cell Death in  
Neonatal Rats  
AUTHOR(S): Kalmar, B.; Burnstock, G.; Vrbova, G.; Urbanics, R.;  
Csermely, P.; Greensmith, L.  
CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement  
Disorders, Institute of Neurology, London, WC1N 3BG,  
UK  
SOURCE: Experimental Neurology (2002), 176(1), 87-97  
CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Heat shock proteins (hsps) are induced in a variety of cells following periods of stress, where they promote cell survival. In this study, we examined the effect of upregulating hsp expression by treatment with BRX-220, a co-inducer of hsps, on the survival of injured motoneurons. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220. The expression of hsp70 and hsp90, motoneurone survival, and muscle function was examined at various intervals later and the number of functional motor units was assessed by in vivo isometric tension recordings. Fourteen days after injury, significantly more motoneurons survived in the BRX-220-treated group ( $39 \pm 2.8\%$ ) compared to the saline-treated group ( $21 \pm 1.7\%$ ). Moreover, in the BRX-220-treated group no further loss of motoneurons occurred, so that at 10 wk  $42 \pm 2.1\%$  of motoneurons survived compared to  $15 \pm 0.6\%$  in the untreated group. There were also more functional motor units in the hindlimb muscles of BRX-220-treated animals. In addition, treatment with BRX-220 resulted in a significant increase in the expression of hsp70 and hsp90 in glia and neurons. Thus, treatment with BRX-220, a co-inducer of hsps, protects motoneurons from axotomy-induced cell death.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:418232 CAPLUS

DOCUMENT NUMBER: 138:49725

TITLE: Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats

AUTHOR(S): Rakonczay, Zoltan; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Nemeth, Ilona; Lonovics, Janos; Takacs, Tamas

CORPORATE SOURCE: First Department of Medicine, University of Szeged, Szeged, Hung.

SOURCE: Free Radical Biology & Medicine (2002), 32(12), 1283-1292

CODEN: FRBMEH; ISSN: 0891-5849

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nontoxic heat shock protein (HSP) inducer compds. open up promising therapeutic possibilities by activating one of the natural and highly conserved defense mechanisms of the organism. In the present expts., we examined the effects of a HSP coinducer drug-candidate, BRX-220, on the cholecystokinin-octapeptide (CCK)-induced acute pancreatitis in rats. Male Wistar rats weighing 240 to 270 g were divided into two groups. In group B, 20 mg/kg BRX-220 was administered orally, followed by 75  $\mu$ g/kg CCK s.c. three times, after 1, 3, and 5 h. This whole procedure was repeated for 5 d. The animals in group B received physiol. saline orally instead of BRX-220, but otherwise the protocol was the same as in group B. The rats were exsanguinated through the abdominal aorta 12 h after the last administration of CCK. We determined the serum amylase activity, the plasma trypsinogen activation peptide concentration, the pancreatic weight/body weight ratio, the DNA and total protein contents of the pancreas, the levels of pancreatic HSP60 and HSP72, the activities of pancreatic amylase, lipase, trypsinogen, and free radical scavenger enzymes (superoxide dismutase, catalase, and glutathione peroxidase), the degree of lipid peroxidn.,

protein oxidation, and the reduced glutathione level. Histopathol. investigation of the pancreas was also performed in all cases. Repeated CCK treatment resulted in the typical laboratory and morphol. changes of exptl. induced pancreatitis. The pancreatic levels of HSP60 and HSP72 were significantly increased in the animals treated with BRX-220. In group B, the pancreatic total protein content and the amylase and trypsinogen activities were significantly higher vs. group B. The plasma trypsinogen activation peptide concentration, and the pancreatic lipid peroxidn., protein oxidation, and the activity of Cu/Zn-superoxide dismutase were significantly decreased in group B vs. group B, whereas the glutathione peroxidase activity was increased. The morphol. damage in group B was significantly lower than that in group B. The HSP coinducer BRX-220, administered for 5 d, has a protective effect against CCK-induced acute pancreatitis.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:780856 CAPLUS

DOCUMENT NUMBER: 135:318423

TITLE: Preparation of  
N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine,  
N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, and enantiomers thereof.

INVENTOR(S): Ueroegdi, Laszlo; Jeges Csakai, Zita; Gruber, Lajos; Oetvoes, Laszlo; Toth, Jozsef; Toemoeskoezi, Istvan; Szakacs Schmidt, Aniko; Reider, Ferencne; Schneidern Barlay, Maria

PATENT ASSIGNEE(S): Biorex Kutato es Fejleszt, Hung.

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079174	A1	20011025	WO 2001-HU46	20010417 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
HU 2000001583	A2	20021128	HU 2000-1583	20000418 <--
CA 2406266	A1	20011025	CA 2001-2406266	20010417 <--
EP 1274685	A1	20030115	EP 2001-928133	20010417 <--
EP 1274685	B1	20060712		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001010184	A	20030617	BR 2001-10184	20010417 <--
JP 2004501080	T	20040115	JP 2001-576775	20010417 <--
EE 200200591	A	20040415	EE 2002-591	20010417 <--
EE 5085	B1	20081015		
NZ 522017	A	20040625	NZ 2001-522017	20010417 <--
CN 1216868	C	20050831	CN 2001-810831	20010417

RU 2281282	C2	20060810	RU 2002-130710	20010417
AT 332894	T	20060815	AT 2001-928133	20010417
AU 2001254997	B2	20061123	AU 2001-254997	20010417
ES 2267758	T3	20070316	ES 2001-928133	20010417
IL 152337	A	20071031	IL 2001-152337	20010417
BG 107199	A	20030731	BG 2002-107199	20021016 <--
NO 2002005015	A	20021216	NO 2002-5015	20021018 <--
NO 323535	B1	20070604		
ZA 2002008460	A	20031020	ZA 2002-8460	20021018 <--
MX 2002010320	A	20040906	MX 2002-10320	20021018 <--
IN 2002KN01301	A	20050311	IN 2002-KN1301	20021018
KR 742482	B1	20070725	KR 2002-714047	20021018
US 20040006232	A1	20040108	US 2003-257755	20030128 <--
US 7126002	B2	20061024		
HK 1055741	A1	20060407	HK 2003-108135	20031110

PRIORITY APPLN. INFO.:

HU 2000-1583	A	20000418
WO 2001-HU46	W	20010417

OTHER SOURCE(S): CASREACT 135:318423

AB Title compds. were prepared Thus, 2-hydroxy-4-azoniaspiro[3.5]nonane chloride was stirred in aqueous NaOH for 40 min. at 5-10°; EtOH and 3-pyridinamidoxime 1-oxide (preparation given) was added and the mixture was refluxed 2 h to give 62% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidine. The latter in aqueous HCl at -5° was treated with aqueous NaNO<sub>2</sub> followed by stirring for 1.5 h to give 85% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:608728 CAPLUS

DOCUMENT NUMBER: 133:207815

TITLE: Preparation of  
N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

INVENTOR(S): Kurthy, Maria; Biro, Katalin; Nagy, Karoly; Urogdi, Laszlo; Csakai, Zita; Szilbereky, Jeno; Mogyorosi, Tamas; Torok, Magdolna; Komaromi, Andras; Marvanyos, Ede; Barabas, Mihaly; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda

PATENT ASSIGNEE(S): Biorex Kutato Es Fejleszt Rt., Hung.

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050403	A1	20000831	WO 2000-HU15	20000224 <--
W: AU, BG, BR, CA, CZ, EE, HR, IL, IN, JP, KR, LT, LV, NO, PL, RO, RU, SI, SK, UA, US, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2360451	A1	20000831	CA 2000-2360451	20000224 <--
BR 2000008969	A	20011127	BR 2000-8969	20000224 <--
EP 1163224	A1	20011219	EP 2000-909542	20000224 <--
EP 1163224	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2002537384	T	20021105	JP 2000-600986	20000224 <--
EE 200100447	A	20021216	EE 2001-447	20000224 <--
EE 4961	B1	20080215		
AT 237590	T	20030515	AT 2000-909542	20000224 <--
PT 1163224	T	20030731	PT 2000-909542	20000224 <--
ES 2193055	T3	20031101	ES 2000-909542	20000224 <--
AU 779096	B2	20050106	AU 2000-31824	20000224
RU 2250901	C2	20050427	RU 2001-126126	20000224
CZ 297386	B6	20061115	CZ 2001-3053	20000224
IL 144866	A	20070704	IL 2000-144866	20000224
PL 197692	B1	20080430	PL 2000-350915	20000224
IN 2001KN00785	A	20050311	IN 2001-KN785	20010731
ZA 2001006488	A	20020807	ZA 2001-6488	20010807 <--
HR 2001000584	A1	20020831	HR 2001-584	20010807 <--
BG 105837	A	20020329	BG 2001-105837	20010822 <--
BG 65178	B1	20070531		
NO 2001004103	A	20011022	NO 2001-4103	20010823 <--
NO 319793	B1	20050912		
US 6649628	B1	20031118	US 2001-913263	20011218 <--
PRIORITY APPLN. INFO.:			HU 1999-475	A 19990226
			WO 2000-HU15	W 20000224

AB N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers, and their acid addition salts, useful in treatment of pathol. insulin resistance, and for the treatment of pathol. conditions associated therewith, for the treatment of pathol. insulin resistance, were prepared

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 14 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005111731 EMBASE  
 TITLE: [Mice and humans [8]].  
 Mus og menn.  
 AUTHOR: Holmoy, Trygve  
 CORPORATE SOURCE: Ulleval Universitetssykehus.  
 SOURCE: Tidsskrift for den Norske Laegeforening, (26 Aug 2004) Vol. 124, No. 16, pp. 2156.  
 Refs: 2  
 ISSN: 0029-2001 CODEN: TNLAAH  
 COUNTRY: Norway  
 DOCUMENT TYPE: Journal; Letter  
 FILE SEGMENT: 037 Drug Literature Index  
 008 Neurology and Neurosurgery  
 LANGUAGE: Norwegian  
 ENTRY DATE: Entered STN: 24 Mar 2005  
 Last Updated on STN: 24 Mar 2005

L5 ANSWER 10 OF 14 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004177118 EMBASE  
 TITLE: Putting the heat on ALS.  
 AUTHOR: Benn, Susanna C. (correspondence); Brown Jr., Robert H.  
 CORPORATE SOURCE: Day Lab. for Neuromuscular Research, Massachusetts General Hospital, Charlestown, MA 02129, United States. sbenn@partners.org; rhbrown@partners.org  
 SOURCE: Nature Medicine, (Apr 2004) Vol. 10, No. 4, pp. 345-347.  
 Refs: 15  
 ISSN: 1078-8956 CODEN: NAMEFI  
 COUNTRY: United Kingdom  
 DOCUMENT TYPE: Journal; (Short Survey)  
 FILE SEGMENT: 030 Clinical and Experimental Pharmacology

037 Drug Literature Index  
005 General Pathology and Pathological Anatomy  
008 Neurology and Neurosurgery  
LANGUAGE: English  
ENTRY DATE: Entered STN: 28 May 2004  
Last Updated on STN: 28 May 2004

L5 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2003:32824 BIOSIS  
DOCUMENT NUMBER: PREV200300032824  
TITLE: Effect of BRX-220 against peripheral  
neuropathy and insulin resistance in diabetic rat models.  
AUTHOR(S): Kurthy, Maria [Reprint Author]; Mogyorosi, Tamas; Nagy,  
Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi,  
Laszlo; Biro, Katalin  
CORPORATE SOURCE: Biorex Research and Development Company, P. O. Box 348,  
Veszprem-Szabadsagpuszta, H-8201, Hungary  
Maria.Kurthy@biorex.hu  
SOURCE: Klimes, Iwar [Editor, Reprint Author]; Sebokova, Elena  
[Editor]; Howard, Barbara V. [Editor]; Ravussin, Eric  
[Editor]. (2002) pp. 482-489. Lipids and insulin  
resistance: The role of fatty acid metabolism and fuel  
partitioning. print.  
Publisher: New York Academy of Sciences, 2 East 63rd  
Street, New York, NY, 10021, USA. Series: Annals of the New  
York Academy of Sciences.  
Meeting Info.: Fourth International Smolenice Insulin  
Symposium on Lipids and Insulin Resistance: The Role of  
Fatty Acid Metabolism and Fuel Partitioning. Smolenice,  
Slovakia. August 29-September 02, 2001.  
ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-368-8 (cloth),  
1-57331-369-6 (paper).  
DOCUMENT TYPE: Book; (Book Chapter)  
Conference; (Meeting)  
Conference; (Meeting Paper)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 8 Jan 2003  
Last Updated on STN: 11 Feb 2003

L5 ANSWER 12 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2003:32816 BIOSIS  
DOCUMENT NUMBER: PREV200300032816  
TITLE: Comparison of the extrapancreatic action of BRX-  
220 and pioglitazone in the high-fat diet-induced  
insulin resistance.  
AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyorosi, T.; Nagy,  
Karoly; Demcakova, Edita; Ukropec, Jozef; Koranyi, Laszlo;  
Klimes, Iwar [Reprint Author]  
CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute of  
Experimental Endocrinology, Slovak Academy of Sciences,  
Vlarska 3, SK-83306, Bratislava, Slovakia  
ueeniwar@savba.sk  
SOURCE: Klimes, Iwar [Editor, Reprint Author]; Sebokova, Elena  
[Editor]; Howard, Barbara V. [Editor]; Ravussin, Eric  
[Editor]. (2002) pp. 424-430. Lipids and insulin  
resistance: The role of fatty acid metabolism and fuel  
partitioning. print.  
Publisher: New York Academy of Sciences, 2 East 63rd  
Street, New York, NY, 10021, USA. Series: Annals of the New  
York Academy of Sciences.

Meeting Info.: Fourth International Smolenice Insulin Symposium on Lipids and Insulin Resistance: The Role of Fatty Acid Metabolism and Fuel Partitioning. Smolenice, Slovakia. August 29-September 02, 2001. ISSN: 0077-8923 (ISSN print). ISBN: 1-57331-368-8 (cloth), 1-57331-369-6 (paper).

DOCUMENT TYPE: Book; (Book Chapter)  
Conference; (Meeting)  
Conference; (Meeting Paper)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 8 Jan 2003  
Last Updated on STN: 11 Feb 2003

L5 ANSWER 13 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:542301 BIOSIS  
DOCUMENT NUMBER: PREV200200542301  
TITLE: Non-toxic heat shock protein co-inducer BRX-220 protects against acute pancreatitis in rats.  
AUTHOR(S): Rakonczay, Zoltan, Jr. [Reprint author]; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Lonovics, Janos; Takacs, Tamas  
CORPORATE SOURCE: Szeged, Hungary  
SOURCE: Gastroenterology, (April, 2002) Vol. 122, No. 4 Suppl. 1, pp. A-283. print.  
Meeting Info.: Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association. San Francisco, CA, USA. May 19-22, 2002. CODEN: GASTAB. ISSN: 0016-5085.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 23 Oct 2002  
Last Updated on STN: 23 Oct 2002

L5 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:4500 BIOSIS  
DOCUMENT NUMBER: PREV200200004500  
TITLE: Prevention of axotomy-induced motoneuron death by treatment with BRX-220, a co-inducer of heat shock proteins.  
AUTHOR(S): Kalmar, B. [Reprint author]; Burnstock, G.; Vrbova, G.; Hargitai, J.; Urbanics, R.; Greensmith, L. [Reprint author]  
CORPORATE SOURCE: Inst Neurology, University College London, London, UK  
SOURCE: Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 2477. print.  
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001. ISSN: 0190-5295.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 28 Dec 2001  
Last Updated on STN: 25 Feb 2002

AB Heat shock proteins (hsps) are induced in a variety of cells in response to stress. We examined the effect of BRX-220, a co-inducer of hsps, on axotomised motoneurons. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220 (10 mg/kg, i.p.). The effect on motoneuron survival was assessed by counting the number of Nissl-stained motoneurons. The number of

functional motor units was assessed by in vivo isometric tension recordings. Hsp expression was examined both in vivo and in vitro by immunostaining, western blot analysis and Elisa. BRX-220 treatment significantly improved the survival of injured motoneurons. Thus, 39% (+2.8 SEM., n=7) of motoneurons survived 14 days after injury in the treated group compared to only 21% (+1.7 SEM., n=7) in untreated group. This improvement in motoneuron survival was also observed 10 weeks after injury and was reflected in an increase in the number of functional motor units in the hindlimb muscles. The expression of hsp 70 and 90 was found to increase following BRX-220 treatment both in vivo in axotomised spinal cords and in vitro in heat shocked H9c2, 3T3 and Wehi-164 cells, where 10<sup>-5</sup>-10<sup>-6</sup> M BRX-220 increased hsp70 levels by approximately 30 to 50%, as measured by ELISA and western blot analysis. Therefore, BRX-220 protects motoneurons from axotomy-induced cell death. This effect may be due to its ability to act as a co-inducer of hsps. Thus, it may be possible to rescue injured neurons by enhancing their own cellular defence mechanisms.

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.



All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:07:08 ON 23 OCT 2009

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 10:07:33 ON 23 OCT 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 OCT 2009 HIGHEST RN 1189642-14-5

DICTIONARY FILE UPDATES: 22 OCT 2009 HIGHEST RN 1189642-14-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e brx

E1	6	BRWR1/BI
E2	1	BRWY/BI
E3	32 -->	BRX/BI
E4	6	BRX1/BI
E5	2	BRX1A/BI
E6	2	BRX1B/BI
E7	6	BRXE/BI
E8	2	BRXE10/BI
E9	2	BRXE11/BI
E10	2	BRXE12/BI
E11	2	BRXE13/BI
E12	2	BRXE14/BI

=> e brx220

E1	2	BRX1A/BI
E2	2	BRX1B/BI
E3	0 -->	BRX220/BI
E4	6	BRXE/BI
E5	2	BRXE10/BI

E6	2	BRXE11/BI
E7	2	BRXE12/BI
E8	2	BRXE13/BI
E9	2	BRXE14/BI
E10	2	BRXE15/BI
E11	2	BRXE16/BI
E12	3	BRXE2/BI

=> s e3

L1 0 BRX220/BI

=> e brx

E1	6	BRWR1/BI
E2	1	BRWY/BI
E3	32 -->	BRX/BI
E4	6	BRX1/BI
E5	2	BRX1A/BI
E6	2	BRX1B/BI
E7	6	BRXE/BI
E8	2	BRXE10/BI
E9	2	BRXE11/BI
E10	2	BRXE12/BI
E11	2	BRXE13/BI
E12	2	BRXE14/BI

=> s e3

L2 32 BRX/BI

=> d 12 1-32

L2 ANSWER 1 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
 RN 909311-85-9 REGISTRY  
 ED Entered STN: 02 Oct 2006  
 CN Glucagon-like peptide 1 [2-glycine,28-alanine,31-glycine] (human clone  
 WO2006/096515-SEQID-12) fusion protein with peptide (synthetic) fusion  
 protein with transferrin (human) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 20: PN: WO2006096515 SEQID: 12 claimed protein

CN BRX 0585

CN GLP 1Tf

FS PROTEIN SEQUENCE

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 889930-43-2 REGISTRY

ED Entered STN: 28 Jun 2006

CN Protein (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS  
 RADIX)) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank ABG25053

CN GenBank ABG25053 (Translated from: GenBank AY702649)

FS PROTEIN SEQUENCE

MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 889930-42-1 REGISTRY  
ED Entered STN: 28 Jun 2006  
CN DNA (Arabidopsis thaliana strain ecotype-Uk-2 gene BRX (BREVIS RADIX)  
protein cDNA) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AY702649  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 889930-41-0 REGISTRY  
ED Entered STN: 28 Jun 2006  
CN Protein (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS  
RADIX) truncated isoform) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank ABG25052  
CN GenBank ABG25052 (Translated from: GenBank AY702648)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 889930-40-9 REGISTRY  
ED Entered STN: 28 Jun 2006  
CN DNA (Arabidopsis thaliana strain ecotype-Uk-1 gene BRX (BREVIS RADIX)  
protein truncated isoform cDNA plus 3'-flank) (9CI) (CA INDEX NAME)

OTHER NAMES:


CN GenBank AY702648  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 850069-82-8 REGISTRY  
ED Entered STN: 09 May 2005  
CN Propanedioic acid, (6aS,11bR)-3-(acetyloxy)-7,11b-dihydrobenz[b]indeno[1,2-d]pyran-6a,9,10(6H)-triyl trimethyl ester (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 018  
FS STEREOSEARCH  
MF C30 H28 O15  
SR CA  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 688066-21-9 REGISTRY  
ED Entered STN: 01 Jun 2004  
CN Protein (Arabidopsis thaliana gene BRX) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 502923-63-9 REGISTRY  
ED Entered STN: 14 Apr 2003  
CN Amplex BRX (9CI) (CA INDEX NAME)  
ENTE An activator for pectinase mixture biopolishing agent (Color Center S.A., Spain)  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 496816-64-9 REGISTRY

ED Entered STN: 03 Mar 2003

CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN BRX 51

FS STEREOSEARCH

MF C14 H20 Cl N3 O2 . C4 H4 O4

SR CA

LC STN Files: CA, CAPLUS


CM 1

CRN 496816-63-8

CMF C14 H20 Cl N3 O2

Absolute stereochemistry.

Double bond geometry as shown.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 496816-62-7 REGISTRY

ED Entered STN: 03 Mar 2003

CN 3-Pyridinecarboximidoyl chloride, N-[(2S)-2-hydroxy-3-(1-piperidinyl)propoxy]-, [C(Z)]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN BRX 53

FS STEREOSEARCH


MF C14 H20 Cl N3 O2 . C4 H4 O4

SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 496816-61-6  
CMF C14 H20 Cl N3 O2


Absolute stereochemistry. Rotation (-).  
Double bond geometry as shown.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 412507-73-4 REGISTRY  
ED Entered STN: 08 May 2002  
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-a-05-0-UI EST  
(expressed sequence tag)) (CA INDEX NAME)

OTHER NAMES:

CN GenBank BM933144  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 392081-00-4 REGISTRY  
ED Entered STN: 13 Feb 2002  
CN DNA (human clone pDR2 gene BRX breast cancer nuclear receptor-binding  
auxiliary protein cDNA) (CA INDEX NAME)

OTHER NAMES:

CN 469: PN: WO2007132883 PAGE: 41 unclaimed DNA

CN GenBank AF126008  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 388566-72-1 REGISTRY  
ED Entered STN: 31 Jan 2002  
CN BRX-Q (9CI) (CA INDEX NAME)  
ENTE An experimental acrylamido-based ion-exchanger for protein chromatography  
(Bio-Rad Laboratories, Hercules, CA)  
MF Unspecified  
CI PMS, MAN  
PCT Manual registration  
SR CA  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 344670-25-3 REGISTRY  
ED Entered STN: 05 Jul 2001  
CN DNA (mouse strain C57BL/6J clone UI-M-BH3-brx-b-05-0-UI EST  
(expressed sequence tag)) (CA INDEX NAME)

OTHER NAMES:

CN GenBank BI133445  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 326984-24-1 REGISTRY  
ED Entered STN: 13 Mar 2001  
CN DNA (Rattus norvegicus strain Sprague-Dawley clone  
UI-R-CV1-brx-h-03-0-UI EST (expressed sequence tag)) (9CI) (CA INDEX  
NAME)

OTHER NAMES:

CN 410: PN: US20050084872 TABLE: 9 claimed DNA  
CN GenBank BG373361  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK, TOXCENTER, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 308063-34-5 REGISTRY \*

\* Use of this CAS Registry Number alone as a search term in other STN files may result in incomplete search results. For additional information, enter HELP RN\* at an online arrow prompt (=>).

ED Entered STN: 12 Dec 2000

CN Rubber, butadiene, of cis-1,4-configuration (CA INDEX NAME)

OTHER NAMES:

CN Afdene Buna CB 11

CN Ameripol CB

CN Ameripol CB 200

CN Ameripol CB 220

CN Ameripol CB 221

CN B 27

CN B 27 (rubber)

CN B 37

CN B 37 (rubber)

CN BCP 820

CN BR 01

CN BR 10

CN BR 11

CN BR 1208

CN BR 1220

CN BR 1220N

CN BR 1220SG

CN BR 1241

CN BR 1280

CN BR 130B

CN BR 133P

CN BR 150

CN BR 150B

CN BR 150L

CN BR 153A

CN BR 18

CN BR 230

CN BR 305

CN BR 31

CN BR 360L

CN BR 40

CN BR 51

CN BR 60

CN BR 700

CN BR 700 (rubber)

CN BR 701

CN BR 730

CN BR 9000

CN BR 9002

CN BR 9002L

CN BR 9004

CN BR 9053

CN BRX 5000

CN Bud 1207

CN Bud 1254

CN Budene 1207

CN Budene 1208

CN Budene 1254



CN Budene 1280  
CN Budene 207  
CN Nipol BRX 5000

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

MF Unspecified  
CI MAN, CTS  
SR CA

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L2 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 289893-26-1 REGISTRY

ED Entered STN: 21 Sep 2000

CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-  
piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-  
piperidinyl)propoxy]-, 1-oxide, (2Z)-2-butenedioate (1:1) (salt) (9CI)

OTHER NAMES:

CN BRX 220

FS STEREOSEARCH

MF C14 H20 Cl N3 O3 . C4 H4 O4

SR CA


LC STN Files: BIOSIS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR,  
SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 289893-25-0

CMF C14 H20 Cl N3 O3

Absolute stereochemistry.  
Double bond geometry unknown.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



8 REFERENCES IN FILE CA (1907 TO DATE)  
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 222187-17-9 REGISTRY  
ED Entered STN: 07 May 1999  
CN DNA (human clone 11.1/2.2 gene brx protein cDNA plus flanks) (9CI)  
(CA INDEX NAME)  
OTHER NAMES:  
CN DNA (human clone 11.1/2.2 gene brx nuclear receptor-binding auxiliary  
protein Brx cDNA plus flanks)  
CN DNA (human clone 11.1/2.2 gene brx putative rho guanine nucleotide  
exchange factor cDNA plus flanks)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 222187-15-7 REGISTRY  
ED Entered STN: 07 May 1999  
CN Protein (human clone 11.1/2.2 gene brx reduced) (9CI) (CA INDEX  
NAME)  
OTHER NAMES:  
CN Nuclear receptor-binding auxiliary protein Brx (human clone 11.1/2.2  
gene brx reduced)  
CN Putative Rho guanine nucleotide exchange factor (human clone 11.1/2.2  
gene brx reduced)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 215233-82-2 REGISTRY  
ED Entered STN: 08 Dec 1998  
CN Benzenecarboximidamide, N-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-  
N'-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 156  
MF C20 H27 N3 O2 . Cl H  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL  
CRN (774166-55-1)



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 210170-31-3 REGISTRY  
ED Entered STN: 20 Aug 1998  
CN Protein Brx (human) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 203805-20-3 REGISTRY  
ED Entered STN: 08 Apr 1998  
CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-  
(CA INDEX NAME)

OTHER NAMES:

CN BRX 005  
CN BRX 235  
DR 191159-87-2  
MF C14 H20 N4 O  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1907 TO DATE)  
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 23 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 201556-27-6 REGISTRY

ED Entered STN: 19 Feb 1998  
CN BRX 5 (primer) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN BRX 5  
ENTE A polyimide primer (Cytec)  
MF Unspecified  
CI PMS, MAN  
PCT Manual registration  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
4 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 24 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 181858-04-8 REGISTRY  
ED Entered STN: 10 Oct 1996  
CN RNA (measles virus strain Brx hemagglutinin gene  
fragment-complementary) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN GenBank Z80797  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 25 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 164479-36-1 REGISTRY  
ED Entered STN: 07 Jul 1995  
CN RNA (measles virus strain Brx nucleocapsid protein gene fragment)  
(9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Ribonucleic acid (measles virus strain Brx nucleocapsid protein gene  
fragment)  
OTHER NAMES:  
CN GenBank X84879  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: CA, CAPLUS, GENBANK

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 26 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 63394-00-3 REGISTRY \*  
\* Use of this CAS Registry Number alone as a search term in other STN files may  
result in incomplete search results. For additional information, enter HELP  
RN\* at an online arrow prompt (=>).  
ED Entered STN: 16 Nov 1984  
CN Rubber, butadiene (CA INDEX NAME)  
OTHER NAMES:

CN 150L  
CN 150L (rubber)  
CN 60P  
CN A 24  
CN Alkadienes, rubber  
CN Ameripol CB 441  
CN Ameripol CB 880  
CN Asadene  
CN Asadene 35AS  
CN Asadene 35NF  
CN Asadene 55AE  
CN Asadene 55AS  
CN Asadene 55NF  
CN Asadene AS  
CN Asadene NF 35A  
CN Asadene NF 35AS  
CN Asadene NF 50R  
CN Asaprene 610AX  
CN Asaprene 700A  
CN Asaprene 720A  
CN Asaprene 720AX  
CN Asaprene 730AX  
CN Asaprene 755A  
CN Asaprene 756A  
CN Asaprene 760A  
CN Asaprene BR 730A  
CN Austrapol 1220  
CN Bayer 550  
CN Bon RI 1  
CN BR 02L  
CN BR 02LL  
CN BR 1200  
CN BR 1202G  
CN BR 1203  
CN BR 1207  
CN BR 1220L  
CN BR 1220SU  
CN BR 1250  
CN BR 1441  
CN BR 15HB  
CN BR 200  
CN BR 200 (rubber)  
CN BR 23SH  
CN BR 3505  
CN BR 401  
CN BR 401 (rubber)  
CN BR 55F  
CN BR 90  
CN BR 900  
CN BR 9001  
CN BRX 3000

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

DR 62361-95-9, 51426-11-0, 178234-67-8

MF Unspecified


CI PMS, MAN, CTS

PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST,  
CIN, CSCHEM, TOXCENTER

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L2 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 3701-40-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[2-[4'-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]diazenyl]-, sodium salt (1:2) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[[4'-[(2-hydroxy-1-naphthalenyl)azo]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt (9CI)  
CN C.I. Acid Red 99 (7CI)  
CN C.I. Acid Red 99, disodium salt (8CI)  
OTHER NAMES:  
CN Acid Leather Red 2BG  
CN Acid Red 99  
CN Acidine Red RD  
CN Airedale Red RM  
CN Benzyl Fast Red 2BG  
CN Best Acid Milling Red FRS  
CN Brilliant Milling Red  
CN C.I. 23285  
CN Calcocid Milling Red RC  
CN Coomassie Red R  
CN Dynacid Red RS  
CN Elite Fast Red BG  
CN Elite Fast Red R  
CN Elite Fast Red RS  
CN Kayanol Red RS  
CN Levanol Brilliant Red BB  
CN Milling Fast Red R  
CN Milling Fast Red RS  
CN Milling Fast Red RX  
CN Milling Red PRX  
CN Multicuer Red BRX  
CN Naphthalene Leather Red R  
CN Optanol Red R  
CN Pharmanil Red RB  
CN Polar Red GBD  
CN Polar Red R  
CN Shikiso Acid Red RS  
CN Sulfonine Red RS  
CN Suminol Milling Red GRS  
CN Suminol Red RS  
CN Supranol Fast Red RX  
CN Takaoka Acid Red RS  
CN Triacid Fast Red GRS  
MF C34 H26 N4 O8 S2 . 2 Na  
LC STN Files: CA, CAPLUS, CHEMLIST, RTECS\*, TOXCENTER, USPATFULL, USPATOLD  
(\*File contains numerically searchable property data)  
Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)  
CRN (25317-42-4)




● 2 Na

21 REFERENCES IN FILE CA (1907 TO DATE)  
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 2241-61-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,  
3,6a,9,10-tetraacetate, (6aS,11bR)- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,  
tetraacetate (7CI)  
CN Benz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol, 7,11b-dihydro-,  
tetraacetate, (6aS,11bR)- (9CI)  
CN Benz[b]indeno[2,1-d]pyran-3,6a,9,10(6H)-tetrol, 7,10b-dihydro-,  
tetraacetate, (6aS-cis)-  
OTHER NAMES:  
CN BRX 019  
CN Tetraacetylbrazililn  
FS STEREOSEARCH  
MF C24 H22 O9  
LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, MEDLINE, PROUSDDR, SYNTHLINE,  
TOXCENTER  
(\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 1658-56-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1-Naphthalenesulfonic acid, 4-[2-(2-hydroxy-1-naphthalenyl)diazenyl]-,  
sodium salt (1:1) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1-Naphthalenesulfonic acid, 4-[(2-hydroxy-1-naphthalenyl)azo]-, monosodium  
salt (9CI)

CN C.I. Acid Red 88, monosodium salt (8CI)

OTHER NAMES:

CN 11391 Red

CN 2-Naphthol Red J

CN Acid Cardinal G

CN Acid Fast Red A

CN Acid Leather Red ROC

CN Acid Red 88

CN Acid Red A

CN Acid Red A (Chinese)

CN Acid Red AV

CN Acid Red G

CN Acid Rose AV

CN Acid Scarlet G

CN Airedale Red A

CN Amacid Fast Red A

CN Ambicid Fast Red E

CN Anadurm Red A-ROC

CN Anthrosin BRX

CN Apollo Acid Rocceline

CN Atul Acid Fast Red A

CN Azo Acid Red GS

CN Basacid Red 340

CN Benzyl Red ROC

CN Benzyl Red S

CN Brasilan Red S

CN Bucacid Fast Red A

CN C.I. 15620

CN C.I. Acid Red 88

CN Calcocid Fast Red A

CN Cavalene Red A

CN Colacid Red AV

CN Colocid Fast Red A

CN Conacid Red MM

CN Daedo Acid Roccelline NS

CN Dai-ei Roccelline

CN Derma Fur Red R 150

CN Diacid Red A

CN Dinacid Fast Red A

CN Dyacid Red J

CN Dycosacid Red A

CN Eniacid Fast Red A

CN Eriosin Roccelline

CN Eriosin Roccelline SS

CN Ext D and C Red No. 8

CN Fabracid Red S-A

CN Fast Acid Red G

CN Fast Red A


CN Fast Red A (acid dye)

CN Fast Red AE

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for



DISPLAY  
 DR 163442-07-7, 39309-87-0  
 MF C20 H14 N2 O4 S . Na  
 CI COM  
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT,  
 CHEMCATS, CHEMLIST, CSCHEM, DETHERM\*, IFICDB, IFIPAT, IFIUDB, MEDLINE,  
 MSDS-OHS, PIRA, PROMT, RTECS\*, TOXCENTER, USPAT2, USPATFULL, USPATOLD  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (18268-54-7)



● Na

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

452 REFERENCES IN FILE CA (1907 TO DATE)  
 10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 454 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
 RN 1326-85-8 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN C.I. Sulphur Black 2 (8CI, 9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN C.I. 53195  
 CN C.I. Sulfur Black 2  
 CN Calcogene Black 2R-CF  
 CN Calcogene Black RB-CF  
 CN Diresul Black 2R  
 CN Diresul Black 3R  
 CN Diresul Black EV-PL  
 CN Eclipse Deep Black BG  
 CN Fenoxyl Black 2R  
 CN Katigen Deep Black RRND-CF  
 CN Kayaku Sulphur Black BRX  
 CN Mitsui Sulphur Black ABR  
 CN Mitsui Sulphur Black BBRO  
 CN Mitsui Sulphur Black BR  
 CN Mitsui Sulphur Black R  
 CN Mitsui Sulphur Black RC  
 CN Nissen Black BRX

CN Sodyesul Black MCF  
 CN Solfo Black 3R  
 CN Solfo Black R  
 CN Sulfanol Black 2R  
 CN Sulfogene Carbon 4RCF  
 CN Sulfogene Carbon MCF  
 CN Sulfogene Carbon Supra CF Grains  
 CN Sulfogene Carbon T  
 CN Sulfogene Grey H1A grai  
 CN Sulfur Black 2  
 CN Sulfur Black 2RD  
 CN Sulfur Black 4RD  
 CN Sulfur Black DR  
 CN Sulfur Black RND  
 CN Sulphol Black BSP  
 CN Sulphol Black BSP Paste  
 CN Sulphol Black No. 44  
 CN Sulphol Black PG  
 CN Sulphol Black PXR Ex. Conc  
 CN Sulphol Black PXR Paste  
 CN Sulphol Black RS Grains  
 CN Sulphol Liquid Black QR  
 CN Sulphur Black 2  
 CN Thionol Black R  
 DEF This substance is identified in the COLOUR INDEX by Colour Index  
 Constitution Number, C.I. 53195.  
 MF Unspecified  
 CI MAN  
 LC STN Files: CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, TOXCENTER, USPAT2,  
 USPATFULL  
 Other Sources: NDSL\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
  
 \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 11 REFERENCES IN FILE CA (1907 TO DATE)  
 11 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
  
 L2 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN  
 RN 1064-48-8 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[2-(4-  
 nitrophenyl)diazenyl]-6-(2-phenyldiazenyl)-, sodium salt (1:2) (CA INDEX  
 NAME)  
 OTHER CA INDEX NAMES:  
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[(4-nitrophenyl)azo]-6-  
 (phenylazo)-, disodium salt (9CI)  
 CN Amido Black 10B (6CI)  
 OTHER NAMES:  
 CN Acid Black 1  
 CN Acid Black 10A  
 CN Acid Black 10B  
 CN Acid Black 10BA  
 CN Acid Black 10BN  
 CN Acid Black 10BX  
 CN Acid Black 12B  
 CN Acid Black 4BN  
 CN Acid Black 4BNU  
 CN Acid Black 8GB  
 CN Acid Black Base M  
 CN Acid Black BRX  
 CN Acid Black BX  
 CN Acid Black H

CN Acid Black JVS  
 CN Acid Blue Black  
 CN Acid Blue Black 10B  
 CN Acid Blue Black 10BX  
 CN Acid Blue Black B  
 CN Acid Blue Black BG  
 CN Acid Blue Black Double 600  
 CN Acid Blue Black Sh  
 CN Acid Leather Blue IGW  
 CN Acid Leather Dark Blue G  
 CN Acid Leather Fast Blue Black G  
 CN Acidal Black 10B  
 CN Acidal Black MV  
 CN Acidal Navy Blue 3BR  
 CN Aciderm Black E 10B  
 CN Acilan Black 10B  
 CN Airedale Black 2BG  
 CN Amacid Black 10BR  
 CN Amide Black 10B  
 CN Amido Black  
 CN Amido Blue Black 12B  
 CN Apollo Acid Blue Black 10B  
 CN Atul Acid Black 10BX  
 CN Atul Acid Black BX  
 CN Azanol Fast Acid Black 10B  
 CN Azo Dark Blue C 2B  
 CN Azo Dark Blue HR  
 CN Azo Dark Blue S  
 CN Azo Dark Blue SH  
 CN Best Acid Dark Blue B  
 CN Black 401  
 CN Black No. 401  
 CN Blue Black 12B  
 CN Blue Black SX

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

DR 12042-02-3, 68417-62-9, 84842-81-9, 86923-11-7, 31258-44-3

MF C22 H16 N6 O9 S2 . 2 Na

CI COM


LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA,  
 CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, IFICDB, IFIPAT,  
 IFIUDB, MEDLINE, MSDS-OHS, PROMT, RTECS\*, TOXCENTER, USPAT2, USPATFULL,  
 USPATOLD

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (3121-74-2)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

976 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

978 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2009 ACS on STN

RN 147-14-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Copper, [29H,31H-phthalocyaninato(2-)-  
κN29,κN30,κN31,κN32]-, (SP-4-1)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 29H,31H-Phthalocyanine, copper complex

CN 29H,31H-Phthalocyanine, copper deriv.

OTHER NAMES:

CN (Phthalocyaninato)copper

CN α-Copper phthalocyanine

CN α-Copper phthalocyanine blue

CN α-Phthalocyanine blue

CN β-Copper phthalocyanine blue

CN β-Phthalocyanine blue

CN ε-Copper phthalocyanine

CN 127EPS

CN 405D

CN 7075M

CN 79S26C

CN 79S26C chip

CN A 220

CN Accosperse Cyan Blue GT

CN Acnalin Supra Blue G

CN Acramin Blue F 3G

CN Akrochem 626

CN Aqualine Blue

CN Aquis BW 3571

CN Arlocyanine Blue PS

CN Aztech Chemisperse Cyan 1541

CN B 2G-L

CN B 4G-KR

CN B 702W

CN B 705H

CN B 736

CN B 8M25

CN Bahama Blue BC

CN Bahama Blue BNC

CN Bahama Blue Lake NCF

CN Bahama Blue WD

CN Bermuda Blue

CN BFD 1121

CN BGS 1

CN BGSG-C

CN BL 1531

CN Blue 7110V

CN Blue BT 627D

CN Blue GLA

CN Blue GLA-SD

CN Blue GLSM

CN Blue Microdis

CN Blue phthalocyanine α-form

CN Blue pigment

CN Blue Toner GTNF

CN BRS 1

CN BRX

CN BSS 4342

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

DR 807622-86-2, 819860-69-0, 819860-85-0, 878390-73-9, 924902-00-1,  
1082606-32-3, 12767-67-8, 10482-39-0, 11097-56-6, 11129-84-3, 177529-54-3,  
177646-05-8, 158853-86-2, 172308-31-5, 172826-46-9, 53802-06-5,  
57916-96-8, 57425-52-2, 55819-49-3, 59518-91-1, 59966-88-0, 64333-57-9,  
95660-31-4, 95917-74-1, 96024-35-0, 104921-99-5, 51331-32-9, 115284-42-9,  
60880-51-5, 60937-79-3, 61489-66-5, 61489-77-8, 61537-10-8, 109675-77-6,  
109766-95-2, 66121-19-5, 37223-81-7, 69431-77-2, 78170-27-1, 78413-59-9,  
85255-95-4, 85256-77-5, 92909-14-3, 90452-20-3, 34567-54-9, 39378-75-1,  
39473-10-4, 53028-77-6, 175386-67-1, 184007-78-1, 209343-48-6,  
211564-97-5, 211925-80-3, 213190-86-4, 220971-30-2, 244244-86-8,  
345338-75-2, 392718-62-6, 681847-78-9

MF C32 H16 Cu N8


CI CCS, COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,  
CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM\*, EMBASE,  
GMELIN\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS,  
PIRA, PROMT, RTECS\*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD  
(\*File contains numerically searchable property data)


Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19281 REFERENCES IN FILE CA (1907 TO DATE)  
1351 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
19324 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
78.70	78.92

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:10:26 ON 23 OCT 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Oct 2009 VOL 151 ISS 18  
FILE LAST UPDATED: 22 Oct 2009 (20091022/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 289893-26-1/rn  
8 289893-26-1  
0 289893-26-1D  
L3 8 289893-26-1/RN  
(289893-26-1 (NOTL) 289893-26-1D )

=> d l3 ibib abs 1-8

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:363043 CAPLUS  
DOCUMENT NUMBER: 147:9795  
TITLE: Process for the preparation of  
O-(3-piperidino-2-hydroxy-1-propyl)-hydroxamic acid  
halide derivatives as antidiabetic agents  
INVENTOR(S): Kuerthy, Maria; Biro, Katalin; Nagy, Karoly; Csakai,  
Zita; Ueroegdi, Laszlo; Szilbereky, Jenoe; Mogyorosi,  
Tamas; Toeroek, Magdolna; Barabas, Mihaly; Komaromi,

PATENT ASSIGNEE(S): Andras; Marvanyos, Ede; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda  
 SOURCE: Biorex Kutato es Fejlesztoe Rt., Hung.  
 Hung. Pat. Appl., 31pp.  
 CODEN: HUXXCV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Hungarian  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 2000000552	A2	20011228	HU 2000-552	20000208
PRIORITY APPLN. INFO.:			HU 2000-552	20000208

AB The subject of the invention is N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboxy-imidoyl chloride, its stereoisomers, as well as their acid addition salts. The invention also includes the application of these compds. in the fight against abnormal insulin resistance and for the treatment of related conditions and a process for the treatment of insulin resistance and related abnormal conditions. Another subject of the invention is the pharmaceutical compns. that contain the above named compds. as their active ingredients, along with the usual auxiliary materials and carriers.

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:100113 CAPLUS

DOCUMENT NUMBER: 141:17416

TITLE: The effect of treatment with BRX-220, a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury

AUTHOR(S): Kalmar, B.; Greensmith, L.; Malcangio, M.; McMahon, S. B.; Csermely, P.; Burnstock, G.

CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK

SOURCE: Experimental Neurology (2003), 184(2), 636-647

CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, we examined the effect BRX-220, a co-inducer of heat shock proteins, in injury-induced peripheral neuropathy. Following sciatic nerve injury in adult rats and treatment with BRX-220, the following features of the sensory system were studied: (a) expression of calcitonin gene-related peptide (CGRP); (b) binding of isolectin B4 (IB4) in dorsal root ganglia (DRG) and spinal cord; (c) stimulation-evoked release of substance P (SP) in an in vitro spinal cord preparation and (d) nociceptive responses of partially denervated rats. BRX-220 partially reverses axotomy-induced changes in the sensory system. In vehicle-treated rats there is a decrease in IB4 binding and CGRP expression in injured neurons, while in BRX-220-treated rats these markers were better preserved. Thus,  $7.0 \pm 0.6\%$  of injured DRG neurons bound IB4 in vehicle-treated rats compared to  $14.4 \pm 0.9\%$  in BRX-220-treated animals. Similarly,  $4.5 \pm 0.5\%$  of DRG neurons expressed CGRP in the vehicle-treated group, whereas  $9.0 \pm 0.3\%$  were pos. in the BRX-220-treated group. BRX-220 also partially restored SP release from spinal cord sections to elec. stimulation of primary sensory neurons. Behavioral tests carried out on partially denervated animals showed that BRX-220 treatment did not prevent the emergence of mech. or thermal hyperalgesia. However, oral treatment for 4 wk lead to reduced pain-related behavior suggesting either slowly developing analgesic actions or enhancement of recovery processes. Thus, the morphol. improvement seen in sensory neuron markers was accompanied by

restored functional activity. Therefore, treatment with BRX-220 promotes restoration of morphol. and functional properties in the sensory system following peripheral nerve injury.

OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)  
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587024 CAPLUS  
DOCUMENT NUMBER: 138:130888  
TITLE: Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models  
AUTHOR(S): Kurthy, Maria; Mogyrosi, Tamas; Nagy, Karoly; Kukorelli, Tibor; Jednakovits, Andrea; Talosi, Laszlo; Biro, Katalin  
CORPORATE SOURCE: Biorex Research and Development Company, Veszprem, Hung.  
SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 482-489  
CODEN: ANYAA9; ISSN: 0077-8923  
PUBLISHER: New York Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Bimoclomol (BML), a symptomatic antidiabetic agent, was developed by Biorex R&D Co. to treat diabetic neuropathy and retinopathy. BRX-220, an orally active member of the BRX family, was developed to treat diabetic complications and insulin resistance (IR) as a follow-up compound. The effect of BRX-220 on peripheral neuropathy was examined in rats with diabetes (type 1) induced by administration of a  $\beta$ -cell toxin, streptozotocin (STZ, 45 mg/kg iv). Nerve functions were evaluated by electrophysiol. measurements of muscle motor and sensory nerve conduction velocities (MNCV and SNCV, resp.). MNCV and SNCV decreased in diabetic rats by 25%. A 1-mo preventive treatment with BRX-220 (2.5, 5, 10, and 20 mg/kg po) dose-dependently improved diabetes-related deficits in MNCV (51.3, 71.3, 86.1, and 91.3%) and SNCV (48.9, 68.5, 86.1, and 93.2%). Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes). Severe IR was detected in STZ diabetic and ZDF rats. This resistance was significantly reduced by BRX-220 treatment.

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)  
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:587016 CAPLUS  
DOCUMENT NUMBER: 138:130887  
TITLE: Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance  
AUTHOR(S): Sebokova, Elena; Kurthy, Maria; Mogyrosi, T.; Nagy, Karoly; Demcakova, Edita; Ukropec, Jozef; Koranyi, Laszlo; Klimes, Iwar  
CORPORATE SOURCE: Diabetes and Nutrition Research Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, SK-83306, Slovakia  
SOURCE: Annals of the New York Academy of Sciences (2002), 967(Lipids and Insulin Resistance), 424-430  
CODEN: ANYAA9; ISSN: 0077-8923  
PUBLISHER: New York Academy of Sciences  
DOCUMENT TYPE: Journal



LANGUAGE: English

AB A new Biorex mol., BRX-220, was shown to be effective in animal models of diabetic neuro- and retinopathy. Recent in vitro studies showed that it might also have an insulin-sensitizing action. Therefore, the effect of BRX-220 on insulin sensitivity was compared with the action of pioglitazone (PGZ) in high fat (HF) diet-induced insulin resistance (IR) of rats. Methods-Male Wistar rats were fed for 3 wk a standard chow (PD) or the HF (70-cal%) diet. The HF-fed rats were also given daily BRX-220 (20 mg/kg BW) or PGZ (6 mg/kg BW) by gavage. In vivo insulin action was assessed by the euglycemic hyperinsulinemic clamp. Glucose, insulin, FFA, triglyceride (TG), and glycerol levels in blood were also measured, as well as tissue TG content. Results-Increased levels of fed TG in circulation after HF diet (PD: 2.0 vs. HF: 5.0 mmol/L) were partially corrected by BRX-220 (HF+BRX: 3.8) and normalized by PGZ (HF+PGZ: 2.6). Both mols. prevented the increase in fed serum FFA levels after HF diet (PD: 0.5; HF: 1.8±0.2 mmol/L), with a more pronounced effect of PGZ (HF+BRX: 1.2; HF+PGZ: 0.7). Tissue TG levels increased significantly in response to HF feeding in both liver (HF: 16; PD: 6.4 µmol/g) and skeletal muscle (HF: 7.7; PD: 2.4). This increase was completely normalized by both agents in the liver (HF+BRX: 8.8; HF+PGZ: 8.8), and only partially in the skeletal muscles. HF diet-induced in vivo IR (PD: 25.4; HF: 15.7 mg/kg/min) was significantly reduced by BRX-220 (HF+BRX: 18.7) and PGZ (HF+PGZ: 22.8) treatment. Conclusions-(1) Subchronic administration of BRX-220 leads to an improvement of in vivo insulin action. (2) This insulin-sensitizing effect is, however, not as pronounced as that of PGZ. (3) It is accompanied by a decrease of circulating TG and FFA levels in the postprandial state and (4) by lower TG content in liver and skeletal muscle.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:496814 CAPLUS

DOCUMENT NUMBER: 137:362925

TITLE: Upregulation of Heat Shock Proteins Rescues Motoneurons from Axotomy-Induced Cell Death in Neonatal Rats

AUTHOR(S): Kalmar, B.; Burnstock, G.; Vrbova, G.; Urbanics, R.; Csermely, P.; Greensmith, L.

CORPORATE SOURCE: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, WC1N 3BG, UK

SOURCE: Experimental Neurology (2002), 176(1), 87-97

CODEN: EXNEAC; ISSN: 0014-4886

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Heat shock proteins (hsps) are induced in a variety of cells following periods of stress, where they promote cell survival. In this study, we examined the effect of upregulating hsp expression by treatment with BRX-220, a co-inducer of hsps, on the survival of injured motoneurons. Following sciatic nerve crush at birth, rat pups were treated daily with BRX-220. The expression of hsp70 and hsp90, motoneuron survival, and muscle function was examined at various intervals later and the number of functional motor units was assessed by in vivo isometric tension recordings. Fourteen days after injury, significantly more motoneurons survived in the BRX-220-treated group (39 ± 2.8%) compared to the saline-treated group (21 ± 1.7%). Moreover, in the BRX-220-treated group no further loss of motoneurons occurred, so that at 10 wk 42 ± 2.1% of motoneurons survived compared to 15 ± 0.6% in the untreated

group. There were also more functional motor units in the hindlimb muscles of BRX-220-treated animals. In addition, treatment with BRX-220 resulted in a significant increase in the expression of hsp70 and hsp90 in glia and neurons. Thus, treatment with BRX-220, a co-inducer of hsps, protects motoneurons from axotomy-induced cell death.

OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)  
REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:418232 CAPLUS

DOCUMENT NUMBER: 138:49725

TITLE: Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats

AUTHOR(S): Rakonczay, Zoltan; Ivanyi, Bela; Varga, Ilona; Boros, Imre; Jednakovits, Andrea; Nemeth, Ilona; Lonovics, Janos; Takacs, Tamas

CORPORATE SOURCE: First Department of Medicine, University of Szeged, Szeged, Hung.

SOURCE: Free Radical Biology & Medicine (2002), 32(12), 1283-1292

CODEN: FRBMEH; ISSN: 0891-5849

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nontoxic heat shock protein (HSP) inducer compds. open up promising therapeutic possibilities by activating one of the natural and highly conserved defense mechanisms of the organism. In the present expts., we examined the effects of a HSP coinducer drug-candidate, BRX-220, on the cholecystokinin-octapeptide (CCK)-induced acute pancreatitis in rats. Male Wistar rats weighing 240 to 270 g were divided into two groups. In group B, 20 mg/kg BRX-220 was administered orally, followed by 75 µg/kg CCK s.c. three times, after 1, 3, and 5 h. This whole procedure was repeated for 5 d. The animals in group B received physiol. saline orally instead of BRX-220, but otherwise the protocol was the same as in group B. The rats were exsanguinated through the abdominal aorta 12 h after the last administration of CCK. We determined the serum amylase activity, the plasma trypsinogen activation peptide concentration, the pancreatic weight/body weight ratio, the DNA and total protein contents of the pancreas, the levels of pancreatic HSP60 and HSP72, the activities of pancreatic amylase, lipase, trypsinogen, and free radical scavenger enzymes (superoxide dismutase, catalase, and glutathione peroxidase), the degree of lipid peroxidn., protein oxidation, and the reduced glutathione level. Histopathol. investigation of the pancreas was also performed in all cases. Repeated CCK treatment resulted in the typical laboratory and morphol. changes of exptl. induced pancreatitis. The pancreatic levels of HSP60 and HSP72 were significantly increased in the animals treated with BRX-220. In group B, the pancreatic total protein content and the amylase and trypsinogen activities were significantly higher vs. group B. The plasma trypsinogen activation peptide concentration, and the pancreatic lipid peroxidn., protein oxidation, and the activity of Cu/Zn-superoxide dismutase were significantly decreased in group B vs. group B, whereas the glutathione peroxidase activity was increased. The morphol. damage in group B was significantly lower than that in group B. The HSP coinducer BRX-220, administered for 5 d, has a protective effect against CCK-induced acute pancreatitis.

OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:780856 CAPLUS  
 DOCUMENT NUMBER: 135:318423  
 TITLE: Preparation of  
 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-  
 3-carboxamidine,  
 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-  
 3-carboximidoyl chloride, and enantiomers thereof.  
 INVENTOR(S): Ueroegdi, Laszlo; Jeges Csakai, Zita; Gruber, Lajos;  
 Oetvoes, Laszlo; Toth, Jozsef; Toemoeskoezi, Istvan;  
 Szakacs Schmidt, Aniko; Reider, Ferencne; Schneidern  
 Barlay, Maria  
 PATENT ASSIGNEE(S): Biorex Kutato es Fejleszt, Hung.  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079174	A1	20011025	WO 2001-HU46	20010417
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
HU 2000001583	A2	20021128	HU 2000-1583	20000418
CA 2406266	A1	20011025	CA 2001-2406266	20010417
EP 1274685	A1	20030115	EP 2001-928133	20010417
EP 1274685	B1	20060712		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001010184	A	20030617	BR 2001-10184	20010417
JP 2004501080	T	20040115	JP 2001-576775	20010417
EE 200200591	A	20040415	EE 2002-591	20010417
EE 5085	B1	20081015		
NZ 522017	A	20040625	NZ 2001-522017	20010417
CN 1216868	C	20050831	CN 2001-810831	20010417
RU 2281282	C2	20060810	RU 2002-130710	20010417
AT 332894	T	20060815	AT 2001-928133	20010417
AU 2001254997	B2	20061123	AU 2001-254997	20010417
ES 2267758	T3	20070316	ES 2001-928133	20010417
IL 152337	A	20071031	IL 2001-152337	20010417
BG 107199	A	20030731	BG 2002-107199	20021016
NO 2002005015	A	20021216	NO 2002-5015	20021018
NO 323535	B1	20070604		
ZA 2002008460	A	20031020	ZA 2002-8460	20021018
MX 2002010320	A	20040906	MX 2002-10320	20021018
IN 2002KN01301	A	20050311	IN 2002-KN1301	20021018
KR 742482	B1	20070725	KR 2002-714047	20021018
US 20040006232	A1	20040108	US 2003-257755	20030128
US 7126002	B2	20061024		
HK 1055741	A1	20060407	HK 2003-108135	20031110
PRIORITY APPLN. INFO.:			HU 2000-1583	A 20000418
			WO 2001-HU46	W 20010417
OTHER SOURCE(S):		CASREACT 135:318423		

AB Title compds. were prepared Thus, 2-hydroxy-4-azoniaspiro[3.5]nonane chloride was stirred in aqueous NaOH for 40 min. at 5-10°; EtOH and 3-pyridinamidoxime 1-oxide (preparation given) was added and the mixture was refluxed 2 h to give 62% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboxamidine. The latter in aqueous HCl at -5° was treated with aqueous NaNO<sub>2</sub> followed by stirring for 1.5 h to give 85% N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:608728 CAPLUS

DOCUMENT NUMBER: 133:207815

TITLE: Preparation of N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

INVENTOR(S): Kurthy, Maria; Biro, Katalin; Nagy, Karoly; Urogdi, Laszlo; Csakai, Zita; Szilberek, Jenő; Mogyorosi, Tamas; Torok, Magdolna; Komaromi, Andras; Marvanyos, Ede; Barabas, Mihaly; Kardos, Mihalyne; Nagy, Zoltan; Koranyi, Laszlo; Nagy, Melinda

PATENT ASSIGNEE(S): Biorex Kutató és Fejlesztő Rt., Hung.

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050403	A1	20000831	WO 2000-HU15	20000224
W: AU, BG, BR, CA, CZ, EE, HR, IL, IN, JP, KR, LT, LV, NO, PL, RO, RU, SI, SK, UA, US, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2360451	A1	20000831	CA 2000-2360451	20000224
BR 2000008969	A	20011127	BR 2000-8969	20000224
EP 1163224	A1	20011219	EP 2000-909542	20000224
EP 1163224	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537384	T	20021105	JP 2000-600986	20000224
EE 200100447	A	20021216	EE 2001-447	20000224
EE 4961	B1	20080215		
AT 237590	T	20030515	AT 2000-909542	20000224
ES 2193055	T3	20031101	ES 2000-909542	20000224
AU 779096	B2	20050106	AU 2000-31824	20000224
RU 2250901	C2	20050427	RU 2001-126126	20000224
CZ 297386	B6	20061115	CZ 2001-3053	20000224
IL 144866	A	20070704	IL 2000-144866	20000224
PL 197692	B1	20080430	PL 2000-350915	20000224
IN 2001KN00785	A	20050311	IN 2001-KN785	20010731
ZA 2001006488	A	20020807	ZA 2001-6488	20010807
HR 2001000584	A1	20020831	HR 2001-584	20010807
BG 105837	A	20020329	BG 2001-105837	20010822
BG 65178	B1	20070531		
NO 2001004103	A	20011022	NO 2001-4103	20010823

NO 319793 B1 20050912  
US 6649628 B1 20031118 US 2001-913263 20011218  
PRIORITY APPLN. INFO.: HU 1999-475 A 19990226  
WO 2000-HU15 W 20000224

AB N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl  
chloride, its stereoisomers, and their acid addition salts, useful in  
treatment of pathol. insulin resistance, and for the treatment of pathol.  
conditions associated therewith, for the treatment of pathol. insulin  
resistance, were prepared

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(6 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>